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ABSTRACT
Hypertension (HTN) is a highly prevalent and major risk factor for poor 
cardiovascular and kidney outcomes in chronic kidney disease (CKD). Prior research 
suggests that HTN is underdiagnosed and undertreated in children with CKD. Risk factors 
associated with HTN in CKD among children include worsening kidney function, African 
American race, primary glomerular disease, proteinuria, and non-use of renin-angiotensin-
aldosterone system inhibitors (RAASi). However, the effect of antihypertensive dose on 
blood pressure control in this population is unknown. The objective of this study was to 
determine the effect of antihypertensive dose on blood pressure control in children with 
CKD. We hypothesize that uncontrolled hypertension (uHTN) is associated with lower 
antihypertensive dose.
We developed a novel quantitative tool, the relative dose index (RDI), to analyze the 
effect of dose on blood pressure control, which expresses subject’s daily dose as a ratio 
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between the current daily dose and the maximum potential daily dose, accounting for age, 
weight and if indicated, renal dose adjustments. Cumulative RDI (cRDI) is the sum RDI for 
all antihypertensive agents.
This study was performed on data from the Chronic Kidney Disease in Children 
(CKiD) study, a large North American multicenter longitudinal study on children with CKD. 
A preliminary univariate analysis was performed on multiple clinical, demographic and 
pharmacological variables comparing outcomes of controlled vs. uncontrolled hypertension 
as well as on absence vs. presence left ventricular hypertrophy (LVH), considered a long-
term sequela of uHTN.
A multivariate logistic regression model was developed including relevant covariates. 
cRDI was not found to be significantly associated with uHTN or LVH, and therefore dose 
expressed as cRDI may be an indicator of disease severity. Similar to previous findings, non-
use of RAASi was associated with uHTN. Non-use of diuretics and non-Caucasian, non-
African American race were associated with higher odds of uHTN. Female sex, African 
American race, and use of a calcium channel blocker, diuretic or beta-blocker were 
associated with LVH.
This study is the first quantitative analysis of the effect of antihypertensive dose on 
BP control in children with CKD. The cRDI has potential applications in research areas 
where multiple drugs are used for a single indication and quantitative analysis of the dose-
effect relationship is needed.
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CHAPTER 1
1.INTRODUCTION
Hypertension (HTN) is a major risk factor for developing poor cardiovascular and 
kidney outcomes in patients with chronic kidney disease (CKD)1–6. Children and young 
adults with CKD have age-specific mortality rates which are more than 130-fold higher than 
the general US population, largely due to underlying cardiovascular disease7–9. It is also one 
of the few modifiable risk factors for CKD progression. The benefit of strict blood pressure 
(BP) control, which targets lower BPs than in conventional hypertension management, has 
been shown to reduce mortality and cardiovascular events in the general population in 
addition to delaying kidney disease progression in adults and children with CKD10–12.
Risk factors associated with hypertension in children with CKD include increased 
rate of decline in kidney function, African American race, primary glomerular disease, 
increased severity of proteinuria and non-use of RAASi13. Left ventricular hypertrophy 
(LVH) is considered a long-term sequela of uncontrolled hypertension (uHTN), and has been 
shown to be associated with increased risk for cardiovascular events including myocardial 
infarction and stroke14–16.
Due to its complex pathophysiology, involving multiple mechanistic pathways, 
several classes of antihypertensive agents are used to manage HTN17. The importance of 
strict BP control has been established in adults with CKD and specifically the superiority of 
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ACE-inhibitors and ARBs (combined, these two classes are known as renin-angiotensin 
aldosterone system inhibitors; RAASi) over other antihypertensive classes1,7,18.  
Prospective studies in children have been lacking, however. Recently, the ESCAPE 
trial showed that strict BP control in children with CKD reduced rates of CKD progression 
when compared with conventional blood pressure management10,19. Although RAASi are 
generally considered the first-line agent for treatment of hypertension in children with CKD, 
approximately 50-60% require more than one antihypertensive agent to achieve the goal of 
intensified BP control (<50th percentile)2, and significant variability exists in the choice of 
agents used in clinical practice to control blood pressure (BP)20. Unfortunately, many with 
CKD struggle with HTN despite efforts including lifestyle modification of diet and exercise 
as well as intensive pharmacological management.
Casual blood pressure is the sum of stable basal blood pressure and the variable 
additional pressure resulting from the patient’s current physiological, mental, and metabolic 
stimuli. Unlike in adults where fixed systolic and diastolic BP cutoffs are used to define 
elevated casual blood pressure and hypertension (stages 1 and 2), in children, HTN is defined 
based on blood pressure (BP) percentiles which are derived from population-based data 
(continuous National Health and Nutrition Examination Survey21) and adjusted for age, 
height and gender. 
In 2017, the American Academy of Pediatrics updated the hypertension guidelines 
providing a new definition of hypertension that is based on BP percentiles from a non-obese 
pediatric population (Figure 1). This updated definition replaces the previous definition based 
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on the Fourth Report from 200422, which included obese children in the determination of BP 
percentiles. The new definition also provides for a fixed BP cutoff for children greater than 
13 years of age.
The impact of the new definition on BP diagnosis and treatment is unclear at this 
time, however this study will provide insight into how new the HTN classification scheme 
impacts diagnosis of HTN in the pediatric CKD population of the CKiD study.
The ambulatory blood pressure monitoring study is an additional clinical tool used to 
more accurately assess a patient’s blood pressure over a 24-hour period at their home, 
providing an overview of diurnal (awake and sleep) cycles of blood pressure variation. 
Combining casual BP measurements with ABPM results are used to classify a patient as 
having normal blood pressure, masked hypertension, white-coat hypertension or ambulatory 
hypertension using the scheme in Table 1, and described in more detail in the next chapter.
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Figure 1: Current AAP 2017 vs. Fourth Report 2004 blood pressure classification schemes
Table 1: Ambulatory blood pressure classification scheme
Casual blood pressure
Normal Increased
Normal ABPM study Normal blood pressure White-coat hypertension
Abnormal ABPM study Masked hypertension Ambulatory hypertension
A recent study by Barletta et al (2017) on children with CKD demonstrated that the 
prevalence of HTN increased between the mid-2000s and 2010s, most strikingly apparent 
with the use of 24h ambulatory blood pressure monitoring (ABPM) studies that showed a 
remarkably high percentage of masked hypertension in up to 49% of the cohort. Although 
designed to determine secular trends rather than serving as an epidemiological study, the 
significant percentage of those with masked hypertension in both periods of the study led the 
authors to conclude that HTN in this population is underdiagnosed and likely undertreated13.
Many questions remain regarding the particular choice and dosing strategy of 
antihypertensive agents within this high-risk cohort. While evidence in favor of RAASi is 
available, there remains virtually no data in pediatric patients which compares dosage of 
medication and if one particular medication dosing strategy is more effective. An intriguing 
recent Cochrane meta-analysis in adults found that lower dose combinations of blood 
pressure-lowing medications was at least as effective, and in some cases more effective, than 
typical antihypertensive dosing strategies and in many cases, associated with fewer side 
effects23.
To our knowledge, no studies have been published evaluating the effect of dose on 
blood pressure control in patients with CKD. Therefore, the objective of this study was to 
determine the effect of antihypertensive drug dose on blood pressure control and LVH in 
children using data from the Children with Chronic Kidney Disease (CKiD) Study, the 
largest North American multicenter longitudinal study of children with chronic kidney 
disease.
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CHAPTER 2
2.REVIEW OF LITERATURE
Hypertension in patients with chronic kidney disease
Adults and children with CKD have higher rates of cardiovascular morbidity and 
decline in kidney function if they have hypertension (HTN) compared to those with normal 
blood pressure. A meta-analysis performed by the National Kidney Foundation Kidney 
Disease Outcomes Quality Initiative (NKF KDOQI)™ Clinical Practice Guidelines for CKD 
found that 27 of 32 studies on adult populations with various forms of CKD identified a 
significant relationship between HTN and a more rapid rate of decline in kidney function24. 
Similarly, this relationship was also confirmed among children in a 2003 study based on the 
North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) database, a large 
longitudinal study of children with kidney disease25. In their study, Mitsnefes et al, 
demonstrated that HTN is a highly significant (p=0.003) and independent risk factor for CKD 
progression. Other risk factors identified in the multivariate Cox regression model included 
African American ethnicity, older age, acquired kidney disease and eGFR 
<50mL/min/1.73m2.
The role of HTN in progression of CKD was similarly shown in the CKiD cohort, 
with more rapid progression to end-stage kidney disease (ESKD) of 38% and 67% in both 
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the non-glomerular and glomerular kidney disease cohorts of children with CKD and 
uncontrolled casual blood pressure, respectively.3
Hypertension is associated with higher rates of left ventricular hypertrophy in 
children with CKD, and children with hypertension are at higher risk of having hypertension 
as adults14–16. In adults, left ventricular hypertrophy is associated with higher rates of 
cardiovascular morbidity including myocardial infarction and stroke, as well as 
cardiovascular-related death26. Therefore, early identification and management of 
hypertension may not only benefit children by delaying CKD progression, but also may 
improve their cardiovascular health as adults.
Epidemiology of hypertension in the pediatric chronic kidney disease population: 
prevalence and risk factors
The prevalence of HTN in the pediatric CKD population has a significant degree of 
variability depending on the particular definition of HTN used20. Reports from the NAPRTCS 
and CKiD databases defined solely by baseline measurement of age- height and sex-adjusted 
systolic or dialystolic BP greater than 95th percentile, estimated that 40% and 54% of the 
pediatric CKD population have HTN, respectively25,27. These are likely underestimates as the 
ABPM data was not available in either study and therefore they did not take into 
consideration patients with masked or controlled hypertension27. Based on a broader 
definition including use of antihypertensive agents or blood pressures greater than 2 SD 
above the mean, HTN was found to be the most common complication in children across all 
stages of CKD with a prevalence of 70% in a single-center study in Canada5. This is likely an 
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overestimate as this would include non-hypertensive children taking RAASi due to 
proteinuria.
A study by Flynn et al. showed that characteristics associated with uncontrolled HTN 
included male sex, shorter duration of CKD, and non-use of RAASi27. In that study, among 
subjects receiving antihypertensive medications, male sex, and absence of RAASi use were 
associated with uncontrolled HTN. In those who were not using RAASi, other agents 
including calcium channel blockers (CCB), diuretics, beta-blockers (BB) or other classes of 
antihypertensive medication were presumably being used to manage HTN.
Ambulatory Blood Pressure Monitoring in the 
diagnosis and monitoring of hypertension
The ambulatory blood pressure monitoring (ABPM) study is an additional clinical 
tool to assess blood pressure over a 24-hour period. ABPM has the advantage over clinic BP 
measurements because it can more accurately assess blood pressure status in the subject’s 
home environment while awake and asleep. Using a combination of casual BP measured in 
the clinic and the ABPM study, the clinician can differentiate between normotension and 
masked hypertension on one hand, and between white-coat hypertension (WCH) and 
ambulatory hypertension on the other hand (Figure 2).
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Masked hypertension with an estimated prevalence of 7% in the general pediatric 
population28, but 37-49% in children with CKD (CKiD data), is considered a stronger 
predictor of ESRD and death in adults compared to casual office BP measurements, and is 
associated with higher rates of left ventricular hypertrophy in children with CKD15,29. 
Although in a more recent longitudinal analysis of children with CKD, both office and 
ABPM systolic blood pressure measurements performed similarly in their ability to predict 
the risk for both left ventricular hypertrophy and progression to end stage kidney disease 
(ESKD)30. The long-term implications of white-coat hypertension is less clear with 
conflicting evidence. In the study by Agarwal and Andersen, WCH was not found to be 
associated with increased risk of death or ESKD29. On the other hand patients with WCH 
have been found to have higher rates of metabolic risk factors, left ventricular hypertrophy 
and have higher rates of progression to ambulatory hypertension compared to normotensive 
patients31–33. Increasingly, ambulatory blood pressure monitoring (ABPM) studies are proving 
to be effective tools for research on HTN and have improved our understanding of its 
relationship with various risk factors such as obesity, sodium intake, sedentary lifestyle and 
8
Figure 2: 24-hour ambulatory blood pressure classification scheme
Scheme is based on AHA guidelines37 and adapted from Samuels et al, 2012).Abbreviations: NL 
Normotension, MH Masked hypertension, WCH White-coat hypertension; AH Ambulatory 
hypertension
Casual Blood Pressure
ABPM load ABPM load
<25% ≥25% <25% ≥25%
NL MH WCH AH
MH MH AH AH
<95th percentile >= 95th percentile
ABPM mean
Blood Pressure
<95th percentile
≥95th percentile
psychological stress, as well as in clinical practice for the diagnosis, management and 
monitoring of blood pressure status34–37.
Interpretation of pediatric ABPM studies is widely based on pediatric population-
derived normative values published by Soergel et al38. The primary parameters used in 
interpretation of the ABPM study include BP load which is the percentage of BP 
measurements above the 95th percentile, and BP index, which is the ratio of the average of all 
BP measurements to the 95th percentile. One should note that the normative values for the 
ABPM study differ from those of the casual BP measurements, and cannot be used 
interchangeably. The use of ABPM studies has gained increasing acceptance among 
clinicians and is now considered standard of care in the evaluation of elevated blood pressure 
in children39,40. Unlike NAPRTCS, the CKiD database includes longitudinal data on 
antihypertensive medications and 24-hour ambulatory blood pressure monitoring (ABPM) 
studies. A recent longitudinal multivariate analysis of blood pressure control in the CKiD 
cohort between 2003 and 2013 showed an increase in the prevalence of HTN based on 
ABPM studies from 51 to 63%, of which a significant proportion was attributed to MH13. 
Left ventricular hypertrophy: a clinical parameter for monitoring 
and predicting outcomes among patients with hypertension
Uncontrolled HTN leads to target organ damage that can affect the kidneys, brain, 
eyes, blood vessels and heart26. Left ventricular hypertrophy is a pathophysiological response 
to HTN which can be monitored over time non-invasively using echocardiography. Both 
detection of LVH and its reversal after treatment of HTN are useful in guiding management 
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of HTN and in risk reduction strategies for future cardiovascular events and mortality15,16,26.  
The definition of LVH is based on the left ventricular mass index (LVMI) which in turn is 
derived from an estimated left ventricular mass that is normalized to height2.7 and in adults is 
defined as LVMI >51g/height(m)2.7 . The prevalence of LVH is more difficult to establish in 
children than in adults, as echocardiographic evaluation in children is limited to specific 
disease-related populations such as children with HTN, CKD, heart disease, diabetes and 
other high-risk populations. In addition, somatic growth in children is a significant 
confounding variable in the normalization of LVMI, and therefore a consensus definition of 
LVH is lacking. LVH in children has been variably defined in the literature using 
normalization based on body surface area, lean body mass and age-, sex- and height-adjusted 
percentiles of LVMI height2.7, making its prevalence and clinical interpretation difficult41,42.  
An additional limitation in the CKD population is the relatively high prevalence of short 
stature in this population which results in a positive bias in the determination of LVMI15,43. A 
2014 longitudinal observational study by Kupferman et al showed that LVH, defined based 
on a 95th percentile cutoff of age-, sex, and height adjusted LVMI, was associated with higher 
systolic BP, use of non-RAASi antihypertensive medications, female sex and anemia, in 
children with CKD after adjusting for covariates of glomerular filtration rate, height, age, 
CKD diagnosis and duration of CKD14,30.
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The pharmacological treatment of hypertension in 
children with chronic kidney disease
HTN is a condition that has a complex pathophysiology involving multiple 
mechanisms including fluid overload, activation of RAAS and sympathetic nervous systems 
and endothelial dysfunction2,44 (Figure 3).
Currently in the US, pediatric hypertension guidelines published by the American 
Academy of Pediatrics in 2017 are applicable to the general pediatric population but also 
address specific high-risk groups within the general population including children with CKD. 
In the general pediatric population, after a trial of lifestyle modifications including diet and 
exercise, the choice of a first line pharmacological class or agent among three classes of 
RAASi, CCB and thiazide diuretics is largely left to the clinician and is based on individual 
characteristics pertaining to the patient including the etiology of hypertension, cardiovascular 
11
Figure 3: Pathophysiological mechanisms of hypertension in chronic kidney disease
Source: Hadtstein and Schaefer (2008)2.
Abbreviations: BP blood pressure, CO cardiac output, TPR total peripheral resistance, PTH 
parathyroid hormone, Na sodium
and metabolic risk factors, side effect profile, cost and availability of the agent. Two first-line 
agents are recommended in patients with stage 2 hypertension.
In the CKD population, the importance of adequate blood pressure control has been 
established in adults and children. Stricter target BP (ie, <120/80 in adults and <50th 
percentile in children), have been shown to provide additional benefits in terms of reduced 
cardiovascular events and delayed CKD progression, however a review of the evidence in the 
literature is not unanimous regarding the value of lower BP targets. Whereas the benefit of 
stricter BP control was associated with improved cardiovascular outcomes in the SPRINT12 
trial (adults with high cardiovascular risk) and slower CKD progression in the ESCAPE10 
trial (children with CKD), lower BP targets did not prove beneficial in the ACCORD45 (adults 
with type 2 diabetes mellitus) and AASK1 (African American adults with hypertensive 
kidney disease) trials. Of note, the AASK trial which also compared efficacy of three 
antihypertensive drug classes, demonstrated the renoprotective effects in delaying CKD 
progression with Renin-Angiotensin-Aldosterone System inhibitors (RAASi), compared with 
either calcium channel blockers (CCB) or beta blocker (BB).
Current guidelines on HTN management in the pediatric CKD popoulation are 
derived largely from extrapolation from adult RCTs1,11 and on the ESCAPE trial10 which 
showed the benefit of strict blood pressure control. For children with CKD, RAASi are the 
first line agents recommended in children with CKD stage 3 or higher, or in those with CKD 
stage 1-2 with proteinuria. This recommendation is consistent with Kidney Disease: 
Improving Global Outcomes (KDIGO) and Kidney Disease Outcomes Quality Initiative 
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(KDOQI) guidelines46,47, two international consortia which have taken a leadership role in 
setting guidelines in the management of adults and children with chronic kidney disease.
Regarding thresholds for initiation of therapy and target blood pressures, both groups 
consider BP consistently above the 90th percentile in children with CKD as a critical level of 
clinical intervention. Whereas KDOQI recommends the 90th percentile as the target of 
therapy, the KDIGO group considers it the starting point for initiation of therapy, with the 
target being the 50th percentile or less. This recommendation applies especially in patients 
with proteinuria where hypertension was associated with an even more rapid decline in 
kidney function compared to those without proteinuria13,25,27.
In contrast to the general pediatric population with hypertension, where no clear 
superiority has been demonstrated among three major classes – RAASi, CCB, and thiazide 
diuretic – the choice of RAASi as a first-line antihypertensive agent for children with CKD is 
based on its renoprotective effects resulting in delayed CKD progression as well as reduction 
of proteinuria which is independently associated with delayed CKD progression19,48. Outside 
of the ESCAPE trial, which was performed on a nearly exclusively European Caucasian 
pediatric population with CKD, and was designed to compare BP targets and not 
antihypertensive classes, there are few if any high quality large prospective trials in children 
with CKD that provide good evidence of the long-term outcome benefits of RAASi over 
other classes. An Italian study using the largest European database of pediatric CKD (Italkid), 
found that there was no benefit in taking ACE-inhibitors over other classes of 
antihypertensive medications in terms of CKD progression among those with hypodysplastic 
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nephropathy (the most common form of CKD in children. Despite these limitations, in 2012 
the KIDGO group suggested (grade 2D: very low quality of evidence) RAASi in 
hypertensive children with CKD. Aside from the recommendation of RAASi as first line 
agents in treating HTN in the CKD population, there is no consensus guideline on the use of 
second-line agents in the management of HTN in CKD, except for the general pediatric 
(AAP) guidelines which suggest choosing from one of the remaining first line agents (CCB 
and thiazide diuretic)39.
HTN can also be caused iatrogenically by several drugs that are used by patients with 
CKD including steroids49. The prevalence of HTN in the CKiD study was relatively high 
compared to the 2-4% prevalence in the general pediatric population50, and in a recent 
publication by Barletta et al, only 37-42% of the cohort were classified as normotensive. In 
this group, hypertension was classified as masked (37-49%) or confirmed hypertension (13-
19%) despite the fact that the majority (65-71%) of children were being managed with 
antihypertensive agents, including 56-59% with RAASi, 15-17% with calcium channel 
blockers, and 7-10% with diuretics13.
Quantitative analysis of antihypertensive 
dosing and number of agents
While there is strong evidence advocating the benefit of blood pressure control in 
hypertensive patients overall and in CKD in particular, the question of which dosing strategy 
should be adopted to achieve both short and long-term therapeutic goals is less clear. 
Significant variability in response to therapy from different antihypertensive classes has led 
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to various approaches including combination therapy and monotherapy with systematic 
rotation of drug class to determine the agent resulting in optimal response51. A meta-analysis 
in 2003 based on adult studies showed that combining antihypertensive agents had an 
additive effect in terms of the dose-response relationship, with similar efficacy across all 
major antihypertensive classes with doses as low as 25% of standard dose. At the same time, 
the adverse effects with combination therapy were less than additive, suggesting a potential 
benefit of combination therapy starting with lower than standard doses of two or more 
medications52. Combination therapy of two or more antihypertensive agents taken in 
combination at fixed doses usually lower than standard dose has gained more interest as a 
means of improving medication adherence, reducing adverse effects and achieving 
therapeutic goals over monotherapy53–55.
To our knowledge, however, no study has examined the role of antihypertensive 
dosing and number of agents in the control of HTN in children with CKD. The wide 
variability of practices in pharmacological management and dosing of antihypertensive 
agents, the lack of prospective trials comparing different classes of antihypertensive 
medications, as well as the methodological challenges in quantitative analysis of dosing in 
the pediatric population have proven obstacles in further understanding the high prevalence 
of uHTN in the pediatric CKD population20.
One measure of standardized medication dose called the Defined Daily Dose (DDD) 
was developed in the 1980s by the World Health Organization in order to quantify drug 
utilization across classes for a given condition56,57. The DDD is value assigned by the WHO 
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Collaborating Centre in Oslo, and represents the assumed average maintenance dose per day 
for a drug used for its main indication in adults. Indicators using the DDD can then be used 
in quantitative analysis studies to investigate changes in drug utilization in a population over 
time, compare drug utilization internationally and evaluate the effect of an intervention on 
drug use. For example one indicator, the DDD per 1000 inhabitants per day is most useful for 
analysis of utilization of medications used chronically where prescribed doses are similar to 
the DDD. Importantly, data using DDD give only an estimated consumption rather than an 
accurate assessment of drug use56, and are limited by being sensitive to differences between 
prescribed doses and the corresponding assigned DDD.
16
CHAPTER 3
3.METHODOLOGY
Rationale
This study developed from a gap in our current understanding of hypertension in 
children with CKD. Although hypertension is considered a significant and potent risk factor 
in the progression of chronic kidney disease and in the development of cardiovascular 
comorbidities, the high prevalence of HTN in children with CKD, even among those treated 
with antihypertensive agents has raised the question of underdiagnosis or undertreatment of 
hypertension in this population13. The lack of studies specifically addressing antihypertensive 
dosing in children provided motivation for this study in furthering development of an 
integrated strategy for the optimal management of HTN in the setting of CKD.
Antihypertensive dose-response studies using combination therapies have been 
published for adults23,52,55,58, showing an additive therapeutic effect with reduced adverse 
effects. Similar studies are lacking in children and the more importantly in the particularly 
high-risk pediatric CKD population. To address this gap our group has developed a novel tool 
for the quantitative analysis of antihypertensive dosing, the relative dose index (RDI), which 
represents the ratio between the actual daily antihypertensive dose and the maximum daily 
dose for a given subject, based on age, weight and estimated glomerular filtration rate 
(eGFR). For details on its definition and rationale refer to RDI section in Study Variables 
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below. With this new method of standardizing dose in the CKiD cohort, we aim to better 
understand the factors influencing hypertension among children with CKD.
Our hypothesis was based on the findings from Barletta et al (2017) that hypertension 
in children with chronic kidney disease is undertreated. As such, we hypothesized that drug 
dose, as expressed by the cumulative relative dose index for all antihypertensive medications 
taken by a subject, is lower in children with uHTN (and similarly in MH and AH), and LVH 
when compared to children with cHTN and without LVH, respectively.
Study design
This cross-sectional observational study was based on data obtained from the CKiD 
study (Clinicaltrials.gov identifier NCT00327860), which is a multicenter prospective 
longitudinal observational cohort study of children in North America with mild to moderate 
chronic kidney disease. Although the parent study remains ongoing with recruitment into a 
third cohort, a publicly available, fully-de-identified archived dataset is available through the 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Central 
Repository59. The NIDDK dataset includes data collected on 586 participants in Cohort 1 and 
280 participants in Cohort 2, with comprehensive clinical, demographic, and outcome data 
through December 31, 2015 archived into the public database. This study was considered 
exempt from human subjects research due to its de-identified nature, and the study herein 
was approved by Children’s Mercy Kansas City IRB (ID: 18010022). 
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The CKiD study design and methods have previously been published in detail40. 
Briefly, participants ages 1-16 years with an eGFR between 30 and 90 mL/min per 1.73m2 
were enrolled from 55 pediatric nephrology centers across North America and followed 
annually. The current manual of procedures, detailed study timeline with covariates of 
interest, and detailed study protocol can be obtained via the study website60,61.
A detailed cardiovascular assessment was performed at the third annual study visit 
(V3) which includes an initial physical exam, echocardiography, and ABPM, and these 
measures were repeated subsequently at every odd visit (visits 5, 7, 9, etc). Therefore, all 
measures for this study were taken from the V3 study visit, including socio-demographic, 
clinical and pharmacological factors of interest.
Study population
CKiD Study Inclusion and Exclusion Criteria62:
Inclusion Criteria
• Age between 1 and 16 years (before 17th birthday) for Cohorts 1 and 2; age between 
6 months and 16 years (before 17th birthday) for Cohort 3 
• Estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min|1.73m2 for 
Cohort 1 OR an estimated GFR between 45 and 90 ml/min|1.73m2 based on the 
updated Schwartz formula for Cohort 2 
• Willingness and ability to provide informed consent and assent 
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• For Cohort 2, an equal distribution of children with glomerular and non-glomerular 
causes of disease were enrolled (i.e., 150 within each) and the study placed an upper 
limit of 60% for the percent of enrolled with non-glomerular disease. 
Patients with the non-glomerular diagnoses listed below that meet the initial criteria 
(i.e., duration of kidney disease less than 5 years, and age between 6 months and 16 years 
old) are eligible and do not have to meet additional criteria:
• Branchio-oto-Renal Disease/Syndrome 
• Cystinosis 
• Medullary cystic disease/ juvenile nephronophthisis 
• Methylmalonic Acidemia 
• Oxalosis 
• Polycystic kidney disease (Autosomal recessive)
However, all other patients with non-glomerular diagnoses will require at least two of the 
following conditions. All conditions except for abnormal imaging/biopsy must have occurred 
after the initial 6 months of life and must not be secondary to a current or resolving episode 
of Acute Kidney Injury (AKI):
• significant proteinuria,
1. Age < 2 years old: urine protein to creatinine ratio > 0.5 
2. Age ≥ 2 years old: urine protein to creatinine ratio > 0.2 
• hematuria (for at least 3 months), 
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• evidence of renal tubular disorders, 
• abnormalities detected by kidney biopsy or imaging 
• abnormal kidney function
1. Age < 2 years old: serum creatinine > 0.4 mg/dL 
2. Age ≥ 2 years old: eGFR < 90 ml/min|1.73m2 (eGFR=41.3 x 
height[meter]/creatinine[mg/dL]) 
• Hypertension defined by one of the following:
1. Documented hypertension noted in the medical record by the physician 
2. Current treatment of hypertension 
3. Blood pressure > 95th percentile for age and gender on at least two occasions
Exclusion Criteria
• Renal, other solid organ, bone marrow or stem cell transplantation 
• Dialysis treatment within the past three months 
• Cancer diagnosis or HIV diagnosis/treatment within last twelve months 
• Current pregnancy or pregnancy within past twelve months 
• Inability to complete major data collection procedures 
• Current enrollment in a randomized clinical trial in which the specific treatment is 
unknown 
• Not fluent in English or Spanish 
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• Plans to move out of area of any participating CKiD site (Families can be transferred 
to another CKiD site if they move) 
• History of structural heart disease 
• Genetic syndromes involving the central nervous system (e.g., Downs syndrome) 
• History of severe to profound mental retardation (i.e., IQ less than 40, significant 
impairment in adaptive function and/or inability to independently execute self-care 
skills) 
Additional inclusion and exclusion criteria for this study:
• Participants were taking at least one antihypertensive medication at their third visit, 
and doses for all antihypertensive agents were available
• Measured height, weight and blood pressure
• Required laboratory data: Serum creatinine, serum cystatin-C and serum urea 
nitrogen levels for calculation of blood pressure percentiles and eGFR (see Table 1)
• Successful 24h ambulatory blood pressure monitoring study
• Left ventricular mass index (LVMI, g/m2) based on echocardiogram
Specific exclusion criteria for this study:
• Maximum time difference between any two of the physical exam, medication history, 
echocardiogram and ABPM study exceeding 3 months
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Materials
No special materials were used for this study. Data from the CKiD database was 
imported from relevant files and all analysis was performed using R and RStudio (Versions 
3.5.3 and 1.1.463, respectively). Required R libraries were obtained from CRAN 
Repository63.
Outcome measures
Blood pressure control was the major outcome of interest and as such was evaluated 
on three levels:
1) The primary outcome was whether subjects had controlled hypertension (cHTN) or 
uncontrolled hypertension (uHTN), with the assumption that all patients taking 
antihypertensive agents had a diagnosis of hypertension. Casual blood pressures which were 
obtained in the office were assigned percentiles based on the updated 2017 AAP blood 
pressure guidelines, using the quantile regression algorithm published by Rosner64,65 and 
classified as normotensive, masked hypertension (MH), white-coat hypertension (WCH) or 
ambulatory hypertension (AH) based on the scheme published by Samuels, et al (2012), 
adapted from AHA guidelines37 as shown in Figure 2. The rationale for using Samuels’ 
classification is that their classification scheme classifies those who were previously 
unclassified (normal casual BP, mean ambulatory BP and abnormal BP load) as abnormal, as 
well as those classified as pre-hypertension based on AHA guidelines, due to the increased 
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risk of cardiovascular disease in patients with CKD. uHTN was defined as having either 
masked or ambulatory hypertension. 
2) As a secondary outcome, the subclassifications of uHTN were used and BP status was 
defined as a trichotomous variable with values of controlled hypertension, masked 
hypertension and ambulatory hypertension.
In contrast to the Fourth Report hypertension guidelines, the updated BP percentiles 
are based on a pediatric population where obese children (BMI > 95th percentile) were 
excluded. In addition, fixed adult BP cutoffs are used from a lower age of 13 years (refer to 
Figure 1). To determine the impact of the new guidelines, cross-tabulations of the study 
population’s BP classification using old and new guidelines was performed for both casual 
BP classifications (normotensive, elevated BP/pre-hypertension, stage 1 and stage 2 
hypertension), as well as ABPM classification (NL Normotensive, WCH white-coat 
hypertension, MH masked hypertension, and AH ambulatory hypertension). The proportions 
of subjects reclassified was summarized for each table.
3) As a measure of target organ damage with clinical relevance with respect to 
hypertension, left ventricular hypertrophy absence vs presence was  defined based on LVMI 
according to the cutoff used by the CKiD study protocol (ie, LVMI > 95th percentile using 
age-, sex- and height-adjusted normative tables from Khoury et al41).
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Study variables
Cumulative relative dose index (cRDI)
We developed a new quantitative tool, relative dose index (RDI, Figure 4) which 
expresses dose as a ratio between the current dose and the maximum potential dose, 
accounting for age, weight, and if indicated, renal dose adjustments.
By normalizing dose based on the maximum dose given the individual patient’s age, 
weight and kidney function, the RDI enables a quantitative dose comparison between 
different antihypertensive medications. Theoretically, based on the study by Law et al (2003) 
showing the additive BP-lowering effect of antihypertensive doses from different classes of 
medication, the cumulative effect of multiple antihypertensive agents should be similar to 
that of the the sum of each individual antihypertensive medication. This cumulative dose is 
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Figure 4: Relative dose index algorithm
A ratio of a subject’s current daily dose relative to the maximum potential daily dose is calculated 
based on standard dosing reference (see Appendix A) and patient age, weight and estimated 
glomerular filtration rate.
expressed by adding the RDIs from all antihypertensive medications, and is defined in this 
study as the cumulative RDI (cRDI).
The maximum RDI for each individual medication was limited to 1, in cases where 
subjects were taking greater than maximum dose with the assumption that the dose-response 
curve becomes flattens with increasing supra-maximum doses. The maximum potential dose 
for each antihypertensive medication was based on pediatric hypertension dose references 
published in peer-reviewed journals17,66 when possible, and from Lexicomp Lexi-Drugs67 for 
the remaining medications (see Appendix A). Renal dosing adjustments were based on 
Lexicomp Lexi-Drugs67.
Socio-demographic, clinical and pharmacological factors
A summary of the variables which were included as potential confounding factors in 
the analysis of the effect of drug dose (expressed as cRDI) on BP control in the study 
population is found in Table 2.
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Table 2: Covariates included in analysis
*Estimated glomarular filtration rate calculated using CKiD formula70:
Domain Variable Type Value Notes
Sociodemographic
Age at visit 3 Continuous Years
Sex Binary Male or female
Race Categorical Caucasian, African American or other
Maternal education Categorical
Clinical Time of CKD onset Continuous Years prior to study entry
CKD diagnosis Binary Glomerular or non-glomerular
Proteinuria Continuous
1) Ordinal
2) Binary
Obesity Continuous BMI z-score
Binary
Continuous Based on CKiD formula*
CKD stage Ordinal 1 to 5
Hyperkalemia Binary Serum potassium level ≤ or > 5mmol/L
Family history of hypertension Binary Yes or no
Pharmacological Current steroid use Binary Yes or no
Number of antihypertensive agents Ordinal 1 to 4
Cumulative relative dose index Continuous
Ordinal Tertiles
Mean relative dose index Continuous Average RDI for all agents taken per patient
Antihypertensive class Binary Use or non-use
Estimated based on year of birth and time at visit 
3 (due to de-identified nature of data, precision of 
age is limited to ±1 year)
Self-identified race. Other includes American 
Indian, native Hawaiian, Asian or multiracial
High school or less, some college or college 
graduate
Urine protein:creatinine ratio (Upc, mg/mg 
creatinine)
Normal (Upc<0.5), mild (Upc 0.5-1), 
moderate (Upc 1-2), severe (Upc > 2)
Normal-mild (Upc<1), moderate-severe 
(Upc>1)
Obese (BMI ≥ 95th percentile), non-obese 
(BMI < 95th percentile)
Estimated GFR*
Cutoffs for each stage are based on GFR 
(ml/min/1.73m2): >90, 60-89, 30-59, 15-29, <15
Log-transformed for quantitative analysis 
due to right-skewed distribution
RAASi (includes ACEi and ARB), BB, 
CCB, diuretic, other
eGFR=39.8× height (m)
Scr (mg /dL)
0.456
× 1.8
cysC (mg /L)
0.418
× 30
BUN (mg /dL)
0.079
×1.076male×height (m)
1.4
0.179
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Statistical Approach
Statistical analysis of relative dose index
Table 2 (see next page) provides an overview of the overall study design and analysis. 
For each outcome group (cHTN/uHTN, cHTN/MH/AH, and LVH present/absent), the overall 
study population and each outcome was described based on all the covariates listed in Table 
1. Comparisons between outcomes were performed using the appropriate statistical tests 
based on the type of covariate and outcome and are summarized in Table 3.
Due to its right-skewed distribution in the study population, cRDI was transformed 
using natural log in subsequent univariate comparisons of outcome groups using t-test and 
ANOVA, depending on whether the outcome was dichotomous or trichotomous, respectively.
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Table 3: Statistical tests used in comparing outcome groups
* Outcome types correspond to the number of possible outcomes within each group
(ie, Dichotomous – controlled hypertension vs. uncontrolled hypertension, Left ventricular 
hypertrophy absent vs. present; Trichotomous – controlled hypertension vs. masked hypertension vs. 
ambulatory hypertension)
Covariate type Statistical test (two-sided)
Dichotomous Continuous or ordinal Mann-Whitney U
Binary or categorical χ2 goodness-of-fit
Trichotomous Continuous or ordinal Kruskal-Wallis
Binary or categorical χ2 goodness-of-fit
*Outcome type
Table 4: Overview of data analysis
Type Overview Description
Methodology
1) Blood pressure and hypertension classification
a) Comparison old vs new BP percentiles
i) Classification of clinic blood pressure
ii) Classification of ambulatory blood pressure
b) Impact of new BP percentiles and classification criteria on hypertension 
status
c) Secondary outcome of interest: Left ventricular hypertrophy
2) Relative Dose Index (RDI)
a) Definition and exploratory survey
b) Cumulative and average RDI as new quantitative measures of relative dose
3) Study population selection criteria
a) Chronic Kidney Disease in Children (CKiD) Study eligibility criteria
b) Inclusion and exclusion criteria for this study
1) a) Definition of hypertension in pediatrics (Fourth Report of 2004 vs American 
American Academy of Pediatrics 2017)
    b) Impact of new percentiles and classification scheme on diagnosis of hypertension
- Two-way contingency tables for study population of casual blood pressure and 
ambulatory blood pressure based on Fourth Report vs 2017 AAP
    c) Left ventricular hypertrophy
         - Definition based on left ventricular mass index (LVMI) percentile using age,       
gender and height-adjusted tables from Khoury et al (2009)
2) a) Definition of Relative Dose Index (RDI)
        i) Algorithm to determine RDI based on subjects age, weight, kidney function and 
medication
       ii) Dose reference tables used in calculation of RDI
    b) Distribution of cumulative RDI among study population
3) a) Overview of CKiD study and eligibility criteria
    b) Subject selection for this study
        i) CONSORT flow diagram of study participant exclusions and inclusions
       ii) Issue of time discrepancy of data collection
      iii) Venn diagram of overlapping selection criteria
Descriptive 
statistics and 
univariate analysis
Summary of covariates from Table 1
Sociodemographic
- Age (continuous: years)
- Sex (binary: male/female)
- Race (categorical: Caucasian/African American/other)
- Maternal education (categorical: high school/college/graduate)
Clinical
- Onset of kidney disease (continuous: years before study entry)
- Primary renal diagnosis (binary: glomerular/non-glomerular)
- Proteinuria
     a) categorical based on urine protein:creatinine ratio:
         i) normal (<0.5)/mild (0.5-1)/moderate (1-2)/severe (>2)
        ii) normal-mild/moderate-severe
     b) continuous (urine protein:creatinine ratio)
- Obesity (binary: >95th percentile and continuous: z-score)
- Kidney function
     a) continuous: estimated glomerular filtration rate (mL/min/1.73m2, using 
CKiD formula)
Statistical analysis with outcome group comparisons for:
1) Controlled/uncontrolled hypertension
2) Controlled/masked/ambulatory hypertension
3) Left ventricular hypertrophy (present/absent)
Summary of results (Tables 1-4, for corresponding outcome groups)
- Overall summary of study population (n=240)
- Comparison of outcome groups (1-4) to determine potential covariates influencing 
outcomes:
a) Factors with continuous data: mean+/-sd
   i) Group comparisons with 2 categories (1 and 3): Mann-Whitney U test (two-sided)
   ii) Group comparisons with 3 categories (2): Kruskal-Wallis test (two-sided)
b) Factors with binary or categorical data: count (%)
    i) Group comparison (χ2 goodness-of-fit test)
        → Unadjusted odds ratios (OR) calculated for factors having p-values <0.2
            (reference values for each subgroup 'exposure' in OR noted below corresponding 
table)
    ii) Comparing odds of outcomes:
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Type Overview Description
 b) ordinal (chronic kidney disease stage 1-5)
- Hyperkalemia (binary: serum potassium level ≤ or > 5mmol/L)
- Family history of hypertension (binary: yes/no)
Pharmacological
- Number of antihypertensive agents (ordinal: 1-4)
- Relative Dose Index (RDI)
    a) numeric based on cumulative and average value across agents per subject 
(cRDI)
    b) ordinal based on tertile within study population
- Use of steroids (binary: yes/no)
- Antihypertensive class (binary: RAASi/CCB/diuretic/BB; see abbreviations 
list)
Odds ratio plot (Forest plot) for unadjusted OR with 95% confidence intervals
Relative dose 
index:
Overall and 
subgroup analysis
Comparison of each outcome group for cumulative RDI
Overall and subgroup analysis
1) Controlled hypertension vs. uncontrolled hypertension (t-test)
2) Controlled hypertension vs. masked hypertension vs ambulatory hypertension 
(ANOVA)
3) Left ventricular hypertrophy: present vs. absent (t-test)
Results
a) Figures: Boxplots of log-transformed cRDI
b) Summary Tables:
- mean (sd), p-value
c) Statistical tests
- independent T-test for groups with dichotomous outcomes (1 and 3)
- ANOVA for group with trichotmous outcomes (2)
Relative dose 
index:
Multivariate 
analysis
Multivariate logistic regression based on generalized linear model
1) Controlled hypertension vs uncontrolled hypertension
2) Left ventricular hypertrophy present vs absent
Sensitivity analysis
    a) Exclusion of number of antihypertensive agents
Results
a) Table of OR and 95% confidence intervals for each factor in model
b) Odds ratio plot of adjusted OR with 95% confidence intervals for outcome groups 1 
and 3
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For all analyses, a two-sided statistical test was used with alpha 0.05. Results were 
reported using both exact p-values with 2 significant digits, as well as 95% confidence 
intervals in order to provide the reader with a combination of useful statistical information 
necessary to independently interpret results. For binary or categorical variables, χ2 test for 
goodness-of-fit was performed to compare between all outcomes groups (cHTN vs uHTN; 
cHTN vs MH vs AH; LVH absent vs present).
A descriptive summary of the socio-demographic, clinical and pharmacological 
variables evaluated at the third visit was performed for the overall study population (n=240) 
alongside a comparison of these covariates between primary and secondary outcomes in 
Appendix B Tables B1-3. 
To determine the direction of association between covariates and dichotomous 
outcomes, odds ratios with 95% confidence intervals were calculated for covariates having a 
p-value <0.2. The reference group for the denominator in the odds ratio was noted in each 
corresponding table. To provide a visual summary of potential confounding covariates, an 
odds plot was created for all odds ratios with 95% confidence intervals.
Preliminary analysis of cumulative relative dose index
To evaluate whether antihypertensive dosing as expressed by cRDI, differed in each 
of the outcome groups, a two-sided t-test (for dichotomous outcomes) and ANOVA (for 
trichotomous outcome group of cHTN/MH/AH) was performed on log-transformed cRDI. 
Results are shown in boxplots for each outcome comparison.
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Subgroup analysis was performed to determine whether covariates interacted with 
cRDI at each outcome level. Log-transformed cRDI was used for comparisons for all 
covariate subgroups where the comparison in the descriptive summary (Tables B1-3) yielded 
a p-value <0.2. Also, a specific a priori analysis was performed on the proteinuria covariates 
(a) normal/mild/moderate/severe and (b) normal-mild/moderate-severe, in order to assess the 
potential for bias by indication, because RAASi are indicated as a treatment for proteinuria as 
well as hyeprtension. T-test and one-way ANOVA tests were performed to comparing cRDI 
in the dichotmous and trichotomous outcome groups, respectively (cHTN/uHTN; 
cHTN/MH/AH). No imputation was used in the case of missing data (eg, maternal education, 
hyperkalemia status and family history of hypertension). Missing data was denoted in Tables  
B1-B3 (Appendix B) by the presence of a denominator for corresponding covariates.
Interaction between cRDI and number of agents
Because cRDI is defined as the sum of all RDIs for a given subject, the cRDI will be 
strongly influenced by the number of agents taken. In order to get a better understanding of 
this relationship, cRDI and average RDI were compared by blood pressure status (cHTN vs. 
uHTN) and left ventricular hypertrophy status (absent vs. present) and stratified by number 
of antihypertensive agents. Kruskal-Wallis test was used for statistical comparison between 
groups.
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Multivariate logistic regression models for outcomes
A multivariate analysis was performed using a multivariate generalized linear model 
logistic regression on the dichotomous outcome groups (cHTN/uHTN, LVH absent/present) 
to determine the adjusted odds ratios for each of the covariates on the outcomes of interest. 
Although cRDI did not meet the criteria of p<0.2 in the univariate analysis, since the primary 
focus of this study to examine the effect of antihypertensive dosing on outcomes, it was 
nevertheless included in all models.
In order to evaluate for multicollinearity, variance inflation factors (VIF) were also 
calculated and a cutoff of 5 was considered as an indicator of significant collinearity that 
should be considered for elimination from the model.
Finally, as a sensitivity analysis, models were generated using subjects taking RAASi 
alone to the exclusion of other antihypertensive classes (n=225) in order to assess for 
interactions based on antihypertensive class. Tables corresponding to all models are included 
in the Appendix B for reference.
33
CHAPTER 4
4.RESULTS
Subject selection criteria
A CONSORT diagram summarizing the number of subjects included and excluded 
based on selection criteria described above is shown in Figure 5. Of 708 subjects whose 
demographic information was obtained in the CKiD database, 651 were present at visit 3. Of 
these, additional sequential exclusions were made based on unavailability of necessary data 
or ineligibility for the analysis:
• 36 subjects excluded due to missing BP
• 195 subjects excluded due to unavailable or unsuccessful ABPM studies
• 21 subjects excluded due to eGFR that could not be determined because of missing 
required parameters (serum creatinine, serum BUN, cystatin C)
• 130 subjects not taking antihypertensive agents. Of these subjects, the proportions 
normal blood pressure, masked hypertension, ambulatory hypertension and left 
ventricular hypertrophy present were calculated in Table 5.
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Table 5: Outcomes of subjects not taking antihypertensive agents (n=130)
Outcome n Proportion
Normotensive 48 0.37
Masked hypertension 52 0.40
Ambulatory hypertension 30 0.23
Left ventricular hypertrophy 26 0.20
• 29 subjects excluded due to incomplete medication dose information
• 20 subjects excluded due to exceeding maximum timespan for data collection at the 
third visit.
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Figure 5: CONSORT flow diagram
Overview of subject inclusion and exclusion based on study selection criteria
To further illustrate the last exclusion, a dumbell plot for each subject and their 
respective data collection time points as well as a histogram of maximum time difference in 
days between data collection points was performed (Figure 6). The data collection times used 
included time of ABPM, echocardiography, medication history and physical exam.
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Figure 6: Time differences between data collection at visit 3
a) Histogram of maximum timespan for data collection at visit 3 for 260 eligible subjects. Data 
collection includes: ABPM, physical exam (casual BP and anthropometric measurements), 
echocardiogram and medication history. b) Dumbell plot demonstrating timing of data collection 
for each subject at visit 3. 20 subjects with maximum timespan exceeding 90 days, were excluded 
from study.
Abbreviations: ABPM ambulatory blood pressure monitoring study
a)
b)
Whereas the vast majority of subjects had all relevant data collected within 1 month, 
20 subjects’ data exceeded the arbitrary cutoff of 3 months, and were therefore excluded to 
maintain temporal integrity of the data and validity of the results and analysis.
Since exclusion criteria were additive, rather than sequential, a Venn diagram is 
useful in providing further insight into the inclusion and exclusion criteria for the study 
population (Figure 7).
Regions in the diagram that immediately surround the final study population of 240 
subjects, represent subjects that were excluded due to failing to meet a single inclusion 
criteria. Notable areas with a significant number of exclusion are:
• Not taking any antihypertensive agents (n=159)
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Figure 7: Venn diagram of subject inclusion and exclusion criteria
Regions immediately outside of the central region representing the study population (N=140) 
represent subjects that meet all criteria except for one. (see text for further explanation)
• Lack of successful ABPM study (n=97)
• Data collection time span exceeding 3 months (n=20)
These exclusions will be addressed further in the Discussion section.
Overview of antihypertensive medications
The frequencies of each antihypertensive class used by subjects is non-randomly 
distributed and reflects current guidelines favoring renin-angiotensin aldosterone system 
inhibitors (RAASi, n=218) in the CKD population (Figure 8), which were followed in 
descending order by calcium channel blockers (CCB, n=44), diuretics (n=20), beta-blockers 
(n=12) and others which included alpha-2 stimulators (n=6), sodium channel blockers (n=2) 
and alpha-1 blockers (n=1).
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Figure 8: Frequencies of antihypertensive class use in study population
Note that some patients are taking multiple antihypertensive medications. Sodium channel blocker: 
amiloride
Abbreviations: RAASi Renin-Angiotensin-Aldosterone System Inhibitor, CCB  Calcium Channel 
Blocker, BB Beta-Blocker, alpha2stim central alpha-2 adrenergic agonist
Comparison of Fourth Report and 2017 AAP blood pressure classification schemes
Although the majority of subjects’ BP classification remained unchanged with the 
updated 2017 AAP hypertension classification scheme, compared with the Fourth Report, 
there were a small but significant number of subjects who were reclassified (Figure 9). Of 
these, the majority had a more severe classification with the updated guidelines. This was 
apparent both for the casual BP as well as ambulatory BP classifications.
Of the 240 subjects in the study population, the majority retained the same 
classification (shaded in green), however 12% and 5% of subjects had their casual BP and 
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Casual blood pressure classification
Ambulatory blood pressure classification
Figure 9: Reclassification of blood pressure status using American Academy of Pediatrics (2017) 
blood pressure guidelines
a) Casual blood pressure classification and b) Ambulatory blood pressure classification. Comparisons 
are made between AAP 201739 and the Fourth Report (2004)22 for the study population.
Color key: The green shaded areas represent subjects whose classification remained unchanged. Red 
and blue shaded cells represent subjects who were reclassified to more or less severe BP statuses, 
respectively.
American Academy of Pediatrics (2017)
Normal Elevated Blood Pressure Total
Normal 159 10 0 0 167
Pre-Hypertension 2 24 11 0 37
Hypertension, Stage 1 0 1 22 4 27
Hypertension, Stage 2 0 0 0 7 7
Total 161 35 33 11 240
Hypertension
Stage 1
Hypertension
Stage2
4th Report 
(2004)
American Academy of Pediatrics (2017)
Normal White Coat Hypertension Masked Hypertension Ambulatory Hypertension Total
Normal 102 1 0 0 103
White Coat Hypertension 0 4 0 0 4
Masked Hypertension 0 0 91 10 101
Ambulatory Hypertension 0 0 0 32 32
Total 102 5 91 42 240
4th Report 
(2004)
a)
b)
ambulatory BP status, respectively, reclassified with the updated AAP guideline. Of these, 
almost 90% of the casual BP classification and all of the ambulatory BP classification were 
reclassified to a more severe category of BP. Only 3 subjects had a less severe casual BP 
classification (shaded in blue).
Distribution of cumulative relative dose index in the study population
The distribution of cumulative relative dose index (cRDI) in the study population was 
strongly right-skewed, with a majority of patients having cRDI <0.5 (Figure 10). The 
maximum cRDI was 3.
Interestingly, review of the dosing of the study population revealed 26 subjects (11%) 
who had at least one medication dose higher than the recommended dose references. In 
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Figure 10: Distribution of cumulative relative dose index (cRDI)
Note the strongly right-skewed distribution. In subgroup analyses, cRDI was log-transformed 
with statistical significance testing using t-test or ANOVA.Inset: Q-Q plots of untransformed 
vs. log-transformed cRDI in study population.
addition, 79 subjects (33%) were taking medications that required renal dose adjustment 
based on the subject’s eGFR and medication. The odds of having a medication dosed 
excessively was 1.3 times higher (95% confidence interval: 0.56-3.02, p=0.54) in these 
subjects compared to those who did not require renal dose adjustments.
Descriptive summary of study population based on outcomes
A full description of the study population and the various socio-demogrpahic, clinical 
and pharmacological covariates examined based on blood pressure status and left ventricular 
hypertrophy outcomes is found in Appendix B (Tables B1-3). In this section, selected 
covariates which had corresponding p-values of less than 0.2 with respect to each outcome 
group will be summarized, as they were considered potential confounding variables.
Controlled hypertension vs. uncontrolled hypertension
Unadjusted odds ratios of having uncontrolled hypertension are shown in Figure 11 
for covariates with p-values <0.2. Of the covariates examined, the risk factors that were 
associated with increased odds of having uncontrolled hypertension in descending order 
included (OR [95% CI]):
1. Current use of calcium channel blockers (6.73 [2.72,16.65])
2. African American race: Compared to Caucasians, the OR for uncontrolled 
hypertension among this group was 3.33 [CI 1.26,8.75]. Other races (which included 
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American Indian, Native Hawaiian, Asian or multiracial) also had increased odds of 
uHTN with OR 2.10 [CI 1.09,4.05].
3. Severe proteinuria (urine protein:creatinine ratio > 2): (2.91 [1.16,7.31])
4. Number of agents: Subjects taking two antihypertensive agents concurrently had OR 
2.44 [1.15,5.18] compared to those taking only one agent.
5. Current use of renin-angiotensin-aldosterone inhibitors (RAASi) was associated with 
OR 0.07 [0.02,0.29] of having uncontrolled HTN compared to those who did not take 
this class.
6. cRDI  did not significantly differ among subjects with controlled vs. uncontrolled 
hypertension (t-test p=0.13, Figure 12).
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Figure 11: Unadjusted odds ratios of uncontrolled hypertension for selected covariates
Covariates with p-values  <0.2 in Table B1 from univariate analysis are shown. Error bars represent 
95% confidence intervals.
Reference values for each categorical outcome in parentheses: Race (Caucasian), Proteinuria-4 
levels (Normal, urine pro:cr <0.5), Proteinuria-binary (Normal-Mild), Number of agents (1), 
cumulative relative dose index (1st tertile), Hyperkalemia (K<5 mmol/L), Current antihypertensive 
use (not using)
Abbreviations: RAASi renin-angiotensin-aldosterone system inhibitor, CCB calcium channel 
blocker
Table 6 provides a summary of the overall study population and a comparison 
between controlled vs. uncontrolled hypertension with respect to the selected covariates 
which had corresponding p-values <0.05.
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Figure 12: Comparison of cumulative relative dose index by blood pressure status (controlled vs. 
uncontrolled hypertension)
cRDI was log-transformed and t-test used to compare between controlled vs. uncontrolled 
hypertension groups. For all boxplots the lower and upper hinges correspond to the first and third 
quartiles (the 25th and 75th percentiles).The hinges and middle line of the boxplot represent the 
inter-quartile range (IQR), and median. The upper and lower whiskers extend 1.5 times the IQR from 
the corresponding hinge.
Table 6: Descriptive summary: Controlled vs. uncontrolled hypertension
* P-values based on χ2 goodness-of-fit test for categorical and ordinal covariates. Mann-Whitney U test for continuous and 
ordinal covariates.
** Unadjusted odds ratios [with 95% confidence intervals] calculated for selected factors with p-values <0.2; Reference 
categories for odds ratios are italicized. For drug classes, references are non-use of corresponding class.
Descriptive Statistics p-value* OR** [95% CI]
Race, n (%)
164 (68%) 84 (79%) 80 (60%) 0.0074
25 (10%) 6 (6%) 19 (14%) 3.33 [1.26,8.75]
51 (21%) 17 (16%) 34 (26%) 2.10 [1.09,4.05]
Proteinuria (Urine protein:creatinine ratio)
132 (55%) 65 (61%) 67 (50%) 0.041
34 (14%) 16 (15%) 18 (14%) 1.09 [0.51,2.32]
46 (19%) 19 (18%) 27 (20%) 1.38 [0.70,2.72]
28 (12%) 7 (7%) 21 (16%) 2.91 [1.16,7.31]
166 (69%) 81 (76%) 85 (64%) 0.05
74 (31%) 26 (24%) 48 (36%) 1.76 [1.00,3.10]
0.96 ± 1.48 0.87 ± 1.66 1.03 ± 1.32 0.09
Number of antihypertensive agents
1 190 (79%) 93 (87%) 97 (73%) 0.0081
2 39 (16%) 11 (10%) 28 (21%) 2.44 [1.15,5.18]
3 8 (3%) 3 (3%) 5 (4%) 1.60 [0.37,6.88]
4 3 (1%) 0 (0%) 3 (2%) +
1.27 ± 0.58 1.16 ± 0.44 1.35 ± 0.67 0.0081
Cumulative Relative Dose Index (tertiles & mean)
80 (33%) 39 (36%) 41 (31%) 0.11
80 (33%) 39 (36%) 41 (31%) 1.00 [0.54,1.86]
80 (33%) 29 (27%) 51 (38%) 1.67 [0.89,3.15]
0.57 ± 0.55 0.52 ± 0.55 0.62 ± 0.54 0.2
Antihypertensive Drug Class Use, n (%)
209 (87%) 105 (98%) 104 (78%) <0.001 0.07 [0.02,0.29]
44 (18%) 6 (6%) 38 (29%) <0.001 6.73 [2.72,16.65]
20 (8%) 8 (7%) 12 (9%) 0.84
12 (5%) 0 (0%) 12 (9%) 0.0039 +
9 (4%) 0 (0%) 9 (7%) +
Overall
(N = 240)
Controlled 
Hypertension
(n = 107)
Uncontrolled 
Hypertension
(n = 133)
              
   Caucasian
   African American
   Other
              
   Normal (<0.5)
   Mild [0.5-1.0)
   Moderate [1.0-2.0)
   Severe (>2.0)
     Normal-Mild (<1.0)
     Moderate-Severe (>1.0)
   mean ± sd
              
   mean ± sd
              
   1st tertile (low dose)
   2nd tertile (moderate dose)
   3rd tertile (high dose)
   mean ± sd
              
   Renin-Angiotensin System Inhibitor
   Calcium Channel Blocker
   Diuretic
   Beta-blocker
   Other
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Controlled hypertension vs. masked hypertension 
vs. ambulatory hypertension
When uncontrolled hypertension was subdivided into masked and ambulatory 
hypertension, the following factors were identified as potential confounding factors with p-
values <0.2:
1. Race: A significantly disproportionately high proportion of Caucasians had controlled 
hypertension compared with African Americans and other races (χ2 test p-value 
0.012).
2. Proteinuria: Subjects with severe proteinuria (urine protein:creatinine ratio > 2) were 
significantly more likely to have masked and ambulatory hypertension (p=0.044).
3. Estimated GFR: There was an inconsistent trend for eGFR, with subjects in the 
ambulatory hypertension group having the lowest average eGFR (worst kidney 
function), those with the highest average eGFR in the masked hypertension group, 
and controlled hypertension with an intermediate average eGFR. One-way ANOVA 
test was significant (p=0.011) suggesting these results are non-randomly distributed.
4. Number of antihypertensive agents: There was a strong positive association between 
number of agents and higher chance of having either masked or ambulatory 
hypertension (p=0.0018). The average number of agents in the controlled 
hypertension group was only 1.16 ± 0.44 compared with 1.60 ± 0.91 in subjects with 
ambulatory hypertension.
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5. Cumulative RDI: There was a disproportionately high number (52%) of subjects in 
the third (higher dose) tertile with ambulatory hypertension compared to those in the 
first tertile (14%), with a p-value for one-way ANOVA of 0.0039. A boxplot 
comparing cRDI between controlled, masked and ambulatory hypertension 
demonstrates an increasing trend of cRDI for masked and ambulatory hypertension, 
and is shown in Figure 13.
6. Antihypertensive class: Whereas subjects taking RAASi had a higher chance of 
having controlled hypertension (p<0.001), those taking CCB or BB had higher chance 
of having masked or ambulatory hypertension (p<0.001). Subjects taking diuretics 
did not have a significantly higher chance of having masked or ambulatory 
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Figure 13: Comparison of cumulative relative dose index by blood pressure status (controlled vs. 
masked vs. ambulatory hypertension)
cRDI was log-transformed and comparison made with one-way ANOVA and between each pair of 
outcomes using independent two-sample t-test.
hypertension vs. controlled hypertension (χ2=0.07, p=0.78;  χ2=1.9, p=0.17, 
respectively).
Table 7 provides a summary of the overall study population and a comparison 
between controlled vs. uncontrolled hypertension with respect to the selected covariates 
which had corresponding p-values <0.05.
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Table 7:Descriptive summary: controlled vs. masked vs. ambulatory hypertension
* P-values based on χ2 goodness-of-fit test for categorical and binary covariates. Kruskal-Wallis one-way ANOVA for continuous and 
ordinal covariates 
Descriptive Statistics P-value*
Race, n (%)
164 (68%) 84 (79%) 52 (57%) 28 (67%) 0.012
25 (10%) 6 (6%) 12 (13%) 7 (17%)
51 (21%) 17 (16%) 27 (30%) 7 (17%)
Proteinuria (Urine protein:creatinine ratio)
166 (69%) 81 (76%) 62 (68%) 23 (55%) 0.044
74 (31%) 26 (24%) 29 (32%) 19 (45%)
Estimated GFR
51.81 ± 21.11 51.61 ± 21.07 55.01 ± 19.09 45.38 ± 24.19 0.011
CKD stage
1 1 (0%) 0 (0%) 0 (0%) 1 (2%) 0.017
2 32 (13%) 13 (12%) 7 (8%) 12 (29%)
3 135 (56%) 60 (56%) 54 (59%) 21 (50%)
4 59 (25%) 27 (25%) 27 (30%) 5 (12%)
5 13 (5%) 7 (7%) 3 (3%) 3 (7%)
Number of antihypertensive agents
1 190 (79%) 93 (87%) 71 (78%) 26 (62%) 0.0018
2 39 (16%) 11 (10%) 18 (20%) 10 (24%)
3 8 (3%) 3 (3%) 2 (2%) 3 (7%)
4 3 (1%) 0 (0%) 0 (0%) 3 (7%)
1.27 ± 0.58 1.16 ± 0.44 1.24 ± 0.48 1.60 ± 0.91 0.0018
Cumulative Relative Dose Index (tertiles & mean)
80 (33%) 39 (36%) 35 (38%) 6 (14%) 0.0039
80 (33%) 39 (36%) 27 (30%) 14 (33%)
80 (33%) 29 (27%) 29 (32%) 22 (52%)
Antihypertensive Drug Class Use, n (%)
209 (87%) 105 (98%) 78 (86%) 26 (62%) <0.001
44 (18%) 6 (6%) 17 (19%) 21 (50%) <0.001
20 (8%) 8 (7%) 5 (5%) 7 (17%) 0.087
12 (5%) 0 (0%) 5 (5%) 7 (17%) <0.001
9 (4%) 0 (0%) 5 (5%) 4 (10%)
Overall
(N = 240)
Controlled
Hypertension
(n = 107)
Masked
Hypertension
(n = 91)
Ambulatory
Hypertension
(n = 42)
              
   Caucasian
   African American
   Other
              
     Normal-Mild (<1.0)
     Moderate-Severe (>1.0)
              
   mean ± sd
              
              
   mean ± sd
              
   1st tertile (low dose)
   2nd tertile (moderate dose)
   3rd tertile (high dose)
              
   Renin-Angiotensin System Inhibitor
   Calcium Channel Blocker
   Diuretic
   Beta-blocker
   Other
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Absence vs. presence of left ventricular hypertrophy
Unadjusted odds ratios of having left ventricular hypertrophy are shown in Figure 14 
for covariates with p-values <0.2. Of the covariates examined, the risk factors that were 
associated with increased odds of having left ventricular hypertrophy in descending order 
included (OR [95% CI]):
1. Number of antihypertensive agents: There was a strong positive association between 
the number of antihypertensive agents taken by subjects and their odds of having left 
ventricular hypertrophy. Odds ratios for 4, 3 and 2 antihypertensive agents were 18.00 
[1.56,207.92], 5.40 [1.20,24.39] and 3.10 [1.31,7.34], respectively compared to those 
taking only one agent. The average number of agents in the LVH group was 
significantly higher than in the group without LVH (1.65 ± 0.88 vs 1.20 ± 0.49, 
p<0.001).
2. Antihypertensive drug class: Taking a diuretic, beta blocker or calcium channel 
blocker was associated with higher odds of having LVH (4.97 [1.86,13.30], 4.90 
[1.46,16.47], 3.49 [1.59,7.70], respectively. In contrast, those taking a renin-
angiotensin-aldosterone system inhibitor had significantly lower odds of having LVH 
(0.27 [0.11,0.65]).
3. Race: African Americans had higher odds of having LVH compared with Caucasians 
(3.45 [1.36,8.72]).
4. eGFR: Kidney function was significantly lower in subjects with LVH compared to 
those without LVH (eGFR 43.87 ± 20.28 vs. 53.12 ± 21.01, p = 0.02; t-test).
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5. Time of chronic kidney disease (CKD) onset: Onset of CKD before study entry was 
significantly earlier in those without LVH compared to those with LVH (-8.56 years ± 
4.85 years vs  -6.50 years ± 4.02 years, p = 0.021, t-test).
6. Cumulative RDI: There was no significant association with left ventricular 
hypertrophy (unadjusted OR for being in the second and third tertiles compared to the 
first tertile was 1.75 [0.68, 4.48]). A boxplot comparing cRDI between subjects 
without vs with left ventricular hypertrophy did not show any significant differences 
in cRDI, and is shown in Figure 15.
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Figure 14: Unadjusted odds ratios of left ventricular hypertrophy for selected covariates
Error bars represent 95% confidence intervals. Covariates with p-values <0.2 in Table B3 on 
univariate analysis are shown.
Reference values for each categorical outcome in parentheses: Race (Caucasian), CKD stage (1), 
Number of agents (1), Sex (Female), Hyperkalemia (K<5 mmol/L), Current antihypertensive use 
(not using)
Abbreviations: RAASi renin-angiotensin-aldosterone system inhibitor, CCB calcium channel 
blocker, BB beta-blocker, CKD chronic kidney disease, K potassium, BMI body mass index
Table 8 provides a summary of the overall study population and a comparison 
between controlled vs. uncontrolled hypertension with respect to the selected covariates 
which had corresponding p-values <0.05.
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Figure 15: Comparison of cumulative relative dose index by left ventricular hypertrophy status 
(absent vs. present)
cRDI was log-transformed and compared using two-sided t-test (p-value = 0.21).
Table 8: Descriptive summary: absence vs. presence of left ventricular hypertrophy:
* P-values based on χ2 goodness-of-fit test for categorical and ordinal covariates. Mann-Whitney U test for continuous and ordinal 
covariates.
** Unadjusted odds ratios [with 95% confidence intervals] calculated for selected factors with p-values <0.2
Descriptive Statistics P-value* OR [95% CI]**
Race, n (%)
Caucasian 164 (68%) 141 (68%) 23 (68%) <0.001
25 (10%) 16 (8%) 9 (26%) 3.45 [1.36,8.72]
51 (21%) 49 (24%) 2 (6%) 0.25 [0.06,1.10]
CKD onset* (years before study entry)
235; -8.28 ± 4.79 203; -8.56 ± 4.85 32; -6.50 ± 4.02 0.021
Estimated GFR
51.81 ± 21.11 53.12 ± 21.01 43.87 ± 20.28 0.02
Number of antihypertensive agents
1 190 (79%) 171 (83%) 19 (56%) <0.001
2 39 (16%) 29 (14%) 10 (29%) 3.10 [1.31,7.34]
3 8 (3%) 5 (2%) 3 (9%) 5.40 [1.20,24.39]
4 3 (1%) 1 (0%) 2 (6%) 18.00 [1.56,207.92]
1.27 ± 0.58 1.20 ± 0.49 1.65 ± 0.88 <0.001
Cumulative Relative Dose Index (tertiles)
80 (33%) 72 (35%) 8 (24%) 0.26
80 (33%) 67 (33%) 13 (38%) 1.75 [0.68,4.48]
80 (33%) 67 (33%) 13 (38%) 1.75 [0.68,4.48]
Antihypertensive Drug Class Use, n (%)
209 (87%) 185 (90%) 24 (71%) 0.0048 0.27 [0.11,0.65]
44 (18%) 31 (15%) 13 (38%) 0.0027 3.49 [1.59,7.70]
20 (8%) 12 (6%) 8 (24%) 0.0018 4.97 [1.86,13.30]
12 (5%) 7 (3%) 5 (15%) 0.017 4.90 [1.46,16.47]
Overall
(N = 240)
LVH absent
(n = 206)
LVH present
(n = 34)
              
   African American
   Other
              
   n, mean ± sd
              
   mean ± sd
              
   mean ± sd
              
   1st tertile (low dose)
   2nd tertile (moderate dose)
   3rd tertile (high dose)
              
   Renin-Angiotensin System Inhibitor
   Calcium Channel Blocker
   Diuretic
   Beta-blocker
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Subgroup analysis of cumulative relative dose index
Although cumulative relative dose index (cRDI) was not found in the preliminary 
analysis to be significantly associated with blood pressure status (cHTN/uHTN) and LVH, 
when uHTN was subdivided into masked and ambulatory hypertension, there was a positive 
association between cRDI and blood pressure status (Figure 13). Also, the cumulative 
relative dose index (cRDI) is defined as the sum RDI for all antihypertensive agents taken 
concurrently, and therefore number of antihypertensive agents would be expected to be an 
influencing factor on cRDI. Whereas cRDI gives information about the total cumulative dose 
of all antihypertensive agents, mean RDI gives information about the average dose of each 
antihypertensive agent. For example, two hypothetical subjects taking two and three 
antihypertensive agents, respectively with the same cRDI of 1, would have a mean RDI of 
0.5 and 0.33 respectively. Although their cRDI is identical, the lower mean RDI in the latter 
subject would suggest a lower utilization of antihypertensive agents compared with the 
maximum potential dose. Tables 8 and 9 provide an overview of this interaction based on 
blood pressure and left ventricular hypertrophy status, respectively.
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Table 9: Cumulative and mean relative dose index stratified by number of agents and 
grouped by blood pressure status
*P-value obtained using Kruskal-Wallis tests comparing controlled vs. uncontrolled hypertension.
Total (N=240) p value*
1 cumulative RDI 0.44
0.393 (0.268) 0.393 (0.307) 0.393 (0.288)
93 97 190
mean RDI 0.44
0.393 (0.268) 0.393 (0.307) 0.393 (0.288)
93 97 190
2 cumulative RDI 0.179
0.914 (0.659) 1.178 (0.522) 1.104 (0.568)
11 28 39
mean RDI 0.179
0.457 (0.329) 0.589 (0.261) 0.552 (0.284)
11 28 39
3 cumulative RDI 0.024
2.986 (0.024) 0.903 (0.318) 1.684 (1.104)
3 5 8
mean RDI 0.024
0.995 (0.008) 0.301 (0.106) 0.561 (0.368)
3 5 8
4 cumulative RDI
n/a 2.224 (0.489) 2.224 (0.489)
0 3 3
mean RDI
n/a 0.556 (0.122) 0.556 (0.122)
0 3 3
Number of 
antihypertensive 
agents
Controlled 
Hypertension 
(N=107)
Uncontrolled 
Hypertension (N=133)
   Mean (SD)
   N
   Mean (SD)
   N
   Mean (SD)
   N
   Mean (SD)
   N
   Mean (SD)
   N
   Mean (SD)
   N
   Mean (SD)
   N
   Mean (SD)
   N
From Tables 8 and 9, as expected, cRDI tends to increase with increasing number of 
agents. Mean RDI on the other hand did not show a consistent trend, and ranged from 0.3 to 
0.7 for most subjects, suggesting that when taking multiple medications, patients had at least 
one agent that was not being taken at maximum dose. Among children taking 3 
antihypertensive agents, both cRDI and mean RDI were significantly  higher in the controlled 
hypertension group vs. uncontrolled hypertension (cRDI: 2.9 vs 0.9 and mean RDI: 0.95 vs. 
0.3, p=0.02, respectively), however there were only 8 subjects in this stratum. Among the 
subjects taking 2 agents, cRDI and mean RDI were both significantly higher in those without 
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Table 10: Summary of cumulative and mean relative dose index stratified by number of 
antihypertensive agents grouped by left ventricular hypertrophy status
*P-value obtained using Kruskal-Wallis tests comparing left ventricular hypertrophy absent vs. 
present.
No LVH (N=206) LVH (N=34) Total (N=240) p value*
1 cumulative RDI 0.74
0.389 (0.282) 0.431 (0.340) 0.393 (0.288)
171 19 190
mean RDI 0.74
0.389 (0.282) 0.431 (0.340) 0.393 (0.288)
171 19 190
2 cumulative RDI 0.004
1.259 (0.489) 0.654 (0.562) 1.104 (0.568)
29 10 39
mean RDI 0.004
0.629 (0.244) 0.327 (0.281) 0.552 (0.284)
29 10 39
3 cumulative RDI 0.453
2.104 (1.218) 0.985 (0.359) 1.684 (1.104)
5 3 8
mean RDI 0.453
0.701 (0.406) 0.328 (0.120) 0.561 (0.368)
5 3 8
4 cumulative RDI 0.221
2.789 (n/a) 1.942 (0.009) 2.224 (0.489)
1 2 3
mean RDI 0.221
0.697 (n/a) 0.485 (0.002) 0.556 (0.122)
1 2 3
Number of 
antihypertensive 
agents
   Mean (SD)
   N
   Mean (SD)
   N
   Mean (SD)
   N
   Mean (SD)
   N
   Mean (SD)
   N
   Mean (SD)
   N
   Mean (SD)
   N
   Mean (SD)
   N
vs. with left ventricular hypertrophy (1.26 vs 0.65 and 0.63 vs. 0.33, p<0.01, respectively; 
n=39). Together, these suggest that looking within strata by number of agents, higher dose 
may be associated with controlled hypertension and absence of left ventricular hypertrophy.
These sub-analyses of cRDI among controlled vs masked vs ambulatory 
hypertension, on one hand and by number of agents on the other hand, raised the possibility 
of interaction between cRDI and other covariates in the analysis, potentially confounding the 
relationship between hypertension and cRDI. Subgroup analysis of cRDI was expanded to all 
categorical covariates comparing controlled vs. uncontrolled HTN and LVH vs no LVH.
Subgroup analysis: controlled vs. uncontrolled HTN
The only significant differences in cRDI between controlled and uncontrolled 
hypertension were in the subgroups for primary CKD diagnosis (glomerular vs non-
glomerular) and current steroid use (Figure 16). In the glomerular and steroid-taking groups, 
cRDI was significantly higher among those with uncontrolled HTN, compared to those with 
controlled HTN (t-test, p=0.038 and 0.017, respectively).
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Subgroup analysis: left ventricular hypertrophy absent vs. present
Significant differences were noted for the subgroup analysis of number of 
antihypertensive agents (Figure 17). In this comparison, the cRDI was significantly higher in 
the group with no LVH among those taking two antihypertensive agents, whereas there were 
no differences in cRDI between those taking one or three agents.
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Figure 16: Subroups with significant interaction with cRDI: controlled vs. uncontrolled 
hypertension.
Boxplots of cRDI in subgroups: a) Primary CKD diagnosis (glomerular vs. non-glomerular), b) 
Current steroid use (no vs. yes)
Note: T-test of log-transformed cRDI used for statistical comparisons. 
a) b)
Multivariate analysis with logistic regression
The final step in analysis was a multivariate logistic regression model in order to 
adjust for the influence of multiple covariates. For two outcome groups (controlled vs. 
uncontrolled HTN, and LVH absent vs. present) all the covariates were included in the model 
as they were considered clinically relevant factors which may have influence on the blood 
pressure status of the study population. A generalized linear model was used for the logistic 
regression. Proteinuria was categorized as either normal-mild or moderate-severe (urine 
protein:creatinine ratio <1 or ≥1, respectively). Tables for all models are found in Appendix 
C. An odds ratio plot was created from the resulting model to more conveniently identify 
significant covariates.
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Figure 17: Subgroups with significant interaction with cRDI: left ventricular hypertrophy
Boxplots comparing cRDI between subjects with and without left ventricular hypertrophy, in 
subgroups for number of antihypertensive agents. T-test of log-transformed cRDI used for statistical 
comparisons. 
In the first model of uHTN (Figure 18), the only factor significantly associated with 
higher odds of uHTN was race (other), with OR 3.2 [95% CI 1.2-8.0, p=0.01]. Current use of 
diuretics and RAASi was associated with significantly lower odds of uHTN, with OR 0.12 
[95% CI: 0.015-0.712, p=0.03], and OR 0.05 [95% CI: 0.04-0.32, p<0.01]. All other 
covariates were not found to be associated with uHTN. Regarding cRDI, with each increase 
in tertile, the odds of having uHTN increased by 1.2 times (95% CI: 0.75-1.9, p=0.45).
For left ventricular hypertrophy (LVH), in the multivariate logistic regression model 
(Figure 19), odds of having LVH were significantly higher among African Americans (OR 
4.06, 95% CI: 1.0-16.0, p=0.04). Male sex was associated with significantly lower odds of 
LVH (OR 0.22, 95% CI: 0.07-0.67, p=0.01). Having non-African American and non-
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Figure 18: Odds ratio plot from multivariate logistic regression model of uncontrolled hypertension
Error bars denote 95% confidence intervals for odds ratio. Reference categories for variables: Race – 
Caucasian, Current antihypertensive use – non-use, Primary renal disease - glomerular, Current 
steroid use – no, Proteinuria – normal-mild (urine protein:creatinine <1), Sex – female, CKD stage – 
stage 1-3, Family history of hypertension – yes, Obesity – non-obese, Hyperkalemia – no; For 
numeric variables (ie, number of antihypertensive agents, cumulative relative dose index tertile, age), 
the unit of increment is in parentheses.
Caucasian race was also marginally associated with lower odds of LVH (OR 0.17, 95% CI: 
0.01-0.99, p=0.1). The other covariates in the model were not significantly associated with 
LVH. 
Since number of agents was found to have a VIF above the cutoff in models for the 
left ventricular hypertrophy model (6.3), and was close to the cutoff for uncontrolled 
hypertension model (3.6) updated models were created for all dichotomous outcomes 
excluding number of agents. Therefore as part of a sensitivity analysis, the model was 
recreated with the exclusion of number of agents (Figure 20). In the updated model (Figure 
14), in addition to the same factors previously noted, current use of diuretics (OR 4.6, 95% 
CI:1.1-21), CCB (OR 4.4, 95% CI: 1.1-20) and BB (OR 8.0 , 95% CI: 1.1-62) were found to 
be significantly associated with higher odds of LVH (p<0.05 for all OR). Regarding cRDI, 
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Figure 19: Odds plot for multivariate logistic regression of left ventricular hypertrophy.
Error bars represent 95% confidence intervals for odds ratio. Refer to figure 18 for reference 
categories and increments used
for every increase in tertile, the odds of LVH decreased by 0.59 times (95% CI: 0.07-3.2, 
p=0.17).
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Figure 20: Logistic regression adjusted odds ratios for left ventricular hypertrophy after removing 
number of antihypertensive agents due to multicollinearity
Error bars represent 95% confidence intervals for odds ratios. Refer to figure 18 for reference 
categories and increments.
CHAPTER 5
5.DISCUSSION
Impact of updated BP classification on hypertension diagnosis and treatment
This is the first study of the CKiD cohort using updated blood pressure percentiles 
and classification scheme from the 2017 American Academy of Pediatrics guidelines. As 
seen in Figure 9, while the majority of children retained their classification with the new 
guidelines, there were significant proportions of subjects who received a more severe 
classification. For example, of 11 children classified with stage 2 hypertension based on AAP 
2017 guidelines, 4 of these would be classified as stage 1 hypertension using Fourth Report 
guidelines. This pattern of increased severity of classification was apparent for both casual 
BP classification and ABPM classification. At this time, it is difficult to predict the impact 
this will have on long-term kidney and cardiovascular outcomes, however the use of the 
updated hypertension classification is likely to result in improved identification of 
hypertensive children and therefore may potentially reduce undertreatment.
Results of this study in context with previous research
In both the univariate and multivariate analyses, RAASi use was found to be 
associated with lower odds of uncontrolled hypertension (uHTN). African American race was 
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also found to be associated with higher odds of uHTN (univariate analysis) as well as LVH. 
The findings regarding hypertension are consistent with Flynn et al (2008)44, and given the 
known benefits of RAASi in delaying CKD progression and reducing proteinuria, as well as 
the evidence supporting their ability to promote cardiac remodeling in both animal models 
and clinical studies68, these findings would support their continued use in treating 
hypertension, and potentially reducing the risk of LVH in children with CKD. Due to their 
increased risk for CKD progression3, African Americans with CKD and hypertension are 
particularly vulnerable for poor cardiovascular and renal outcomes and as such, Flynn et al. 
(2008) have identified this particular subpopulation as a “top priority of CKD care providers 
[worthy of] aggressive BP control”44.
In addition to these factors, taking more than one antihypertensive agent was found to 
be a risk factor for uHTN as well as LVH (univariate analysis). In Flynn et al (2008), the use 
of 2 or more antihypertensive agents tended to be associated with uncontrolled HTN, 
however did not reach statistical significance. One explanation is that the number of 
antihypertensive agents is potentially a marker of disease severity, and considering that 
RAASi could potentially be used in non-hypertensive proteinuric kidney disease, as a means 
of delaying CKD progression, the use of additional antihypertensive agents could be a more 
sensitive marker for hypertension than use of RAASi alone. This may also explain why non-
RAASi classes of antihypertensive medications (CCB) were associated with higher 
unadjusted odds of uHTN as well as LVH (CCB, BB and diuretics). It is also consistent with 
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Kupferman et al (2014) who found that other antihypertensive classes (non-RAASi) were 
associated with LVH in this population.
The use of diuretics was associated with lower adjusted odds of uncontrolled HTN. 
This is in contrast to their association, along with BB and CCBs, with higher odds of LVH, 
and which has not been previously reported. The significance of this finding is unclear, 
although may be worth considering as combining ACE-inhibitors with diuretics in adults 
patients with diabetic nephropathy showed a particular benefit in reducing proteinuria than 
with other medication combinations69.
Also regarding race, whereas African Americans were at higher risk for uHTN and 
LVH, other non-Caucasian races (Asian, American Indian and Native Hawaiian, multiracial) 
were at higher risk of uHTN but lower risk of LVH when compared with Caucasians. The 
significance of this relationship is also unclear.
Regarding LVH and consistent with previous findings in this pediatric CKD 
population, females were at higher risk of LVH when adjusted for other covariates in the 
model (Figure 19).
Effect of cumulative relative dose index
The major significance of this study is in the novelty of the cRDI as a tool in the 
quantitative analysis of dose and its effect on blood pressure control and left ventricular 
hypertrophy in the pediatric CKD population. Our hypothesis that antihypertensive dose 
would be positively associated with controlled hypertension and absence of LVH was not 
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confirmed in this study. cRDI was not significantly associated with either outcome in both 
the primary and secondary analysis, even when number of agents was removed from the 
multivariate model in a sensitivity analysis (Figure 20). When uncontrolled hypertension was 
subdivided into masked and ambulatory hypertension, however, there was a significant rising 
trend in dose (expressed as log-transformed cRDI) with masked and ambulatory 
hypertension, respectively, compared with controlled hypertension (Figure 13).
Furthermore, from Tables 7 and 8, higher doses were associated with uncontrolled 
HTN and LVH when looking only at subjects with 3 and 2 antihypertensive agents in 
isolation. Although the low number of subjects in the strata limits the overall impact of these 
results, they were in the opposite direction from our hypothesis and could suggest that as 
with number of antihypertensive agents, cRDI may be considered a marker of disease 
severity. In other words, with hypertension, patients may be more likely to take higher doses 
of medication. In light of the distribution of cRDI in the study population, which 
demonstrates that most subjects were taking considerably less than their maximum potential 
dose (Figure 10), we therefore cannot exclude the possibility that with higher doses, subjects 
would have improved blood pressure control.
Differences between DDD defined by WHO and RDI
The RDI measure differs from the defined daily dose (DDD) as defined by the WHO 
in several ways. Firstly, unlike the DDD which uses a standard dose for the entire population, 
cRDI was developed specifically for children where individualized weight-based dosing is 
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often used to prescribe doses. Secondly, the DDD was designed to evaluate drug utilization 
among a population over time in epidemiological studies, whereas the cRDI is designed to 
quantify drug dose in terms of effect, by using maximum dose as the denominator. Finally, 
renal dose adjustments are accounted for in the cRDI by adjusting the maximum dose 
according to each individual child’s eGFR and specific medications which require 
adjustments based on GFR. For these reasons, cRDI is a new concept that has not previously 
been applied, and results from this study will require validation in future studies. If validated, 
cRDI may have potential use in other fields of research as a means of performing a 
quantitative analysis of drug dose when multiple drug classes or medications are used to treat 
a single condition.
Study limitations
There were several limitations in this study:
1. Study population size – Firstly, the statistical power of the analysis was limited by the 
study size of 240 eligible participants, with a relatively large number of potential 
covariates. At the time of obtaining access to the CKiD data from the NIDDK central 
data repository, 651 subjects were present at the third visit. The current data is likely 
to include a larger number of participants which could increase the statistical power 
of the study. The exclusion criteria were necessary to maintain validity of the data and 
answer the research question. Subjects required an ABPM in order to classify their 
blood pressure status, drug doses were needed to calculate RDI, etc. 
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2. Retrospective cross-sectional study design – Since the study design was a 
retrospective cross-sectional analysis at one time point in the CKiD cohort, 
association rather than cause-and-effect are being analyzed. Data that was collected at 
time points beyond a 3-month time span could compromise the validity of the 
analysis. One way to include more data and increase statistical power would be to 
extend the study to follow participants over multiple visits using a mixed effects 
generalized linear model. A longitudinal analysis was beyond the scope of this 
research project, however the current dataset does include data from up to 10 visits or 
9 years of follow-up, leaving an opportunity for future investigation open.
3. Definition of hypertension – The definition of hypertension in this study was limited 
to a single casual BP measurement, whereas clinical guidelines recommend repeated 
measurements taken over several weeks in order to confirm the diagnosis of 
hypertension39. In addition, we did not focus on subjects who were not taking 
antihypertensive medications. In Table 3, we summarized the blood pressure status 
and left ventricular hypertrophy status of these patients not taking antihypertensive 
agents at the third visit, and found that a significant portion of these subjects are 
indeed hypertensive (63%) and had LVH (20%). Although Mitsnefes et al (2003) 
found lower proportions of children with CKD and untreated hypertension in the 
NAPRTCS database, their group did not have ABPM studies available and therefore 
did not take into consideration those with masked hypertension. Regardless, these 
findings point towards a clinical need to diagnose and treat these particularly high-
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risk children in order to reduce their increased rate of CKD progression and higher 
risk of cardiovascular comorbidities.
4. Reported medication use – Since the medication history was obtained from self-
reported or parent-reported questionnaires with the help of a trained interviewer, the 
possibility of medication non-adherence as well as incorrect dose reporting is a 
potential limitation. About 86% of participants did not answer the question about 
frequency of antihypertensive medication non-adherence at the third visit. Of those 
who did, about 83% did report some degree of non-adherence or missed medications 
per week. As a result, while acknowledging this factor as a potential limitation that 
could impact our results, we did not consider it further in analysis.
5. Standard dose references – The relative dose index is based on dose references from 
articles related to treatment of hypertension in children published in peer-reviewed 
journals and a commonly used clinical medication reference tool, Lexicomp17,66,67. 
Dosing guidelines for antihypertensive medications in children is limited due to the 
low rate of FDA-approval of drugs in pediatric hypertension. Although the number of 
clinical drug trials is increasing over time, between 2000 and 2010, only 11 
antihypertensive medications received FDA approval for children. Although there is a 
possibility of prescribers using dose references that do not match the ones used in this 
study, this would not be expected to change the underlying effect of that dose, 
whatever it may be, on blood pressure. Secondly, we used dose references that would 
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be expected to be widely followed by prescribers, in order to minimize the influence 
of this factor on the analysis.
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A. Dose reference table used for calculation of relative dose index
Drug Class max (mg/kg) max (mg) Renal dose adjustment ** Source
Lisinopril ACEi 0.6 40 Chu PY et al.
Benazepril ACEi 0.6 40 Chu PY et al.
Enalapril ACEi 0.58 40 Chu PY et al.
Fosinopril ACEi 0.6 40 Chu PY et al.
Ramipril ACEi * 20 Lexicomp
Captopril ACEi 6 450 Lexicomp
Terazosin alpha-1 blocker * 20 Lexicomp
Clonidine alpha-2 agonist * 2.4
Guanfacine alpha-2 agonist * 2 Lexicomp
Candesartan ARB 0.4 32 Chu PY et al.
Losartan ARB 1.4 100 Chu PY et al.
Valsartan ARB 2.7 160 Chu PY et al.
Olmesartan ARB † 40 Lexicomp
Atenolol BB 2 100 Chu PY et al.
Propranolol BB 4 640 Chu PY et al.
Labetalol BB 12 1200 Lexicomp
Metoprolol BB 6 200 Misurac et al.
Amlodipine CCB 0.6 10 Chu PY et al.
Nifedipine CCB 3 120 Chu PY et al.
Diltiazem CCB 6 360 Lexicomp
Felodipine CCB * 10 Lexicomp
Furosemide diuretic 18 80 Lexicomp
Hydrochlorothiazide diuretic 3 50 Chu PY et al.
Chlorothiazide diuretic 40 2000 Misurac et al.
Amiloride Na-channel blocker 0.625 20 Lexicomp
Hydralazine vasodilator 7.5 200 Misurac et al.
50% if GFR 10-50
25% if GFR<10
75% if GFR 10-50
50% if GFR<10
75% if GFR 10-50
50% if GFR<10
* Maximum dose in mg/kg unavailable
**GFR expressed in units mL/min/1.73m2
† Weight-based dosing for olmesartan: 5-20kg: max = 0.6mg/kg/day, 20-35kg: 
max=20mg/day, >35kg: max=40mg/day.
Abbreviations: ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor 
blocker (ACEi and ARB are collectively referred to as renin-angiotensin-aldosterone system 
inhibitors, RAASi), BB beta-blocker, CCB calcium channel blocker.
B. Descriptive summary of study population by outcomes
Table B1: Controlled vs. uncontrolled hypertension
Descriptive Statistics Overall (N = 240) Controlled Hypertension (n = 107) Uncontrolled Hypertension (n = 133) P-value† OR** [95% CI]
Age (years)               
   mean ± sd 12.80 ± 3.68 12.54 ± 3.48 13.01 ± 3.83 0.23
Sex, n (%)               
   Male 142 (59%) 61 (57%) 81 (61%) 0.63
   Female 98 (41%) 46 (43%) 52 (39%)
Race, n (%)               
   Caucasian 164 (68%) 84 (79%) 80 (60%) 0.0074
   African American 25 (10%) 6 (6%) 19 (14%) 3.33 [1.26,8.75]
   Other 51 (21%) 17 (16%) 34 (26%) 2.10 [1.09,4.05]
Maternal education*, n (%)               
   High school or less 95 (41%) 38 (37%) 57 (45%) 0.33
   Some college 58 (25%) 26 (25%) 32 (25%)
   College graduate 78/231 (34%) 40/104 (38%) 38/127 (30%)
CKD onset* (years before study entry)               
   n, mean ± sd 235; -8.28 ± 4.79 106; -8.35 ± 4.57 129; -8.22 ± 4.98 0.75
CKD diagnosis, n (%)               
   Non-glomerular 154 (64%) 67 (63%) 87 (65%) 0.75
   Glomerular 86 (36%) 40 (37%) 46 (35%)
Proteinuria (Urine protein:creatinine ratio)               
   Normal (<0.5) 132 (55%) 65 (61%) 67 (50%) 0.041
   Mild [0.5-1.0) 34 (14%) 16 (15%) 18 (14%) 1.09 [0.51,2.32]
   Moderate [1.0-2.0) 46 (19%) 19 (18%) 27 (20%) 1.38 [0.70,2.72]
   Severe (>2.0) 28 (12%) 7 (7%) 21 (16%) 2.91 [1.16,7.31]
     Normal-Mild (<1.0) 166 (69%) 81 (76%) 85 (64%) 0.05
     Moderate-Severe (>1.0) 74 (31%) 26 (24%) 48 (36%) 1.76 [1.00,3.10]
   mean ± sd 0.96 ± 1.48 0.87 ± 1.66 1.03 ± 1.32 0.09
BMI z-score               
   <95th %-ile (non-obese) 197 (82%) 88 (82%) 109 (82%) 0.57
   >= 95th %-ile (obese) 43 (18%) 19 (18%) 24 (18%)
   mean ± sd 0.43 ± 1.15 0.37 ± 1.15 0.48 ± 1.15 1
Estimated GFR               
   mean ± sd 51.81 ± 21.11 51.61 ± 21.07 51.97 ± 21.23 0.82
CKD stage               
   1 1 (0%) 0 (0%) 1 (1%) 0.43
   2 32 (13%) 13 (12%) 19 (14%)
   3 135 (56%) 60 (56%) 75 (56%)
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Descriptive Statistics Overall (N = 240) Controlled Hypertension (n = 107) Uncontrolled Hypertension (n = 133) P-value† OR** [95% CI]
   4 59 (25%) 27 (25%) 32 (24%)
   5 13 (5%) 7 (7%) 6 (5%)
Hyperkalemia* (K+ > 5 mmol/L), n (%)               
   No 203 (86%) 86 (82%) 117 (89%) 0.15
   Yes 33/236 (14%) 19/105 (18%) 14/131 (11%) 0.54 [0.26,1.14]
Family history of hypertension*, n (%)               
   Yes 94 (44%) 43 (43%) 51 (44%) 1
   No 121/215 (56%) 56/99 (57%) 65/116 (56%)
Number of antihypertensive agents               
   1 190 (79%) 93 (87%) 97 (73%) 0.0081
   2 39 (16%) 11 (10%) 28 (21%) 2.44 [1.15,5.18]
   3 8 (3%) 3 (3%) 5 (4%) 1.60 [0.37,6.88]
   4 3 (1%) 0 (0%) 3 (2%) +
   mean ± sd 1.27 ± 0.58 1.16 ± 0.44 1.35 ± 0.67 0.0081
Cumulative Relative Dose Index (tertiles & mean)               
   1st tertile (low dose) 80 (33%) 39 (36%) 41 (31%) 0.11
   2nd tertile (moderate dose) 80 (33%) 39 (36%) 41 (31%) 1.00 [0.54,1.86]
   3rd tertile (high dose) 80 (33%) 29 (27%) 51 (38%) 1.67 [0.89,3.15]
   mean ± sd 0.57 ± 0.55 0.52 ± 0.55 0.62 ± 0.54 0.2
Mean Relative Dose Index               
   mean ± sd 0.43 ± 0.29 0.42 ± 0.29 0.43 ± 0.30 0.82
Current Steroids Use, n (%)               
   No 220 (92%) 100 (93%) 120 (90%) 0.51
   Yes 20 (8%) 7 (7%) 13 (10%)
Antihypertensive Drug Class Use, n (%)               
   Renin-Angiotensin System Inhibitor 209 (87%) 105 (98%) 104 (78%) <0.001 0.07 [0.02,0.29]
   Calcium Channel Blocker 44 (18%) 6 (6%) 38 (29%) <0.001 6.73 [2.72,16.65]
   Diuretic 20 (8%) 8 (7%) 12 (9%) 0.84
   Beta-blocker 12 (5%) 0 (0%) 12 (9%) 0.0039 +
   Other 9 (4%) 0 (0%) 9 (7%)
* denotes missing values; please refer to denominator referring to total of known values
† P-values based on Chi-squared goodness-of-fit test for categorical factors (ie, sex, race, CKD diagnosis, obesity, hyperkalemia, family history of hypertension, steroid use, 
antihypertensive drug class use), Mann-Whitney U test for numerical or ordered factors (ie, age, maternal education, CKD onset, proteinuria, BMI z-score, estimated GFR, CKD 
stage, number of antihypertensive agents, cumulative relative dose index tertile, mean relative dose index)
** Unadjusted odds ratios calculated for selected factors with p-values <0.2, + symbol denotes invalid odds ratio due to occurrence of zero values
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Table B1 (continued)
Table B2: Controlled vs. masked vs. ambulatory hypertension
Descriptive Statistics Overall (N = 240) Controlled Hypertension (n = 107) Masked Hypertension (n = 91) Ambulatory Hypertension (n = 42) P-value†
Age (years)               
   mean ± sd 12.80 ± 3.68 12.54 ± 3.48 13.13 ± 3.70 12.76 ± 4.14 0.44
Sex, n (%)               
   Male 142 (59%) 61 (57%) 56 (62%) 25 (60%) 0.81
   Female 98 (41%) 46 (43%) 35 (38%) 17 (40%)
Race, n (%)               
   Caucasian 164 (68%) 84 (79%) 52 (57%) 28 (67%) 0.012
   African American 25 (10%) 6 (6%) 12 (13%) 7 (17%)
   Other 51 (21%) 17 (16%) 27 (30%) 7 (17%)
Maternal education*, n (%)               
   High school or less 95 (41%) 38 (37%) 38 (44%) 19 (48%) 0.58
   Some college 58 (25%) 26 (25%) 21 (24%) 11 (28%)
   College graduate 78/231 (34%) 40/104 (38%) 28/87 (32%) 10/40 (25%)
CKD onset* (years before study entry)               
   n, mean ± sd 235; -8.28 ± 4.79 106; -8.35 ± 4.57 88; -8.15 ± 5.00 41; -8.38 ± 4.99 0.93
CKD diagnosis, n (%)               
   Non-glomerular 154 (64%) 67 (63%) 62 (68%) 25 (60%) 0.57
   Glomerular 86 (36%) 40 (37%) 29 (32%) 17 (40%)
Proteinuria (Urine protein:creatinine ratio)               
   Normal (<0.5) 132 (55%) 65 (61%) 48 (53%) 19 (45%) 0.056
   Mild [0.5-1.0) 34 (14%) 16 (15%) 14 (15%) 4 (10%)
   Moderate [1.0-2.0) 46 (19%) 19 (18%) 17 (19%) 10 (24%)
   Severe (>2.0) 28 (12%) 7 (7%) 12 (13%) 9 (21%)
     Normal-Mild (<1.0) 166 (69%) 81 (76%) 62 (68%) 23 (55%) 0.044
     Moderate-Severe (>1.0) 74 (31%) 26 (24%) 29 (32%) 19 (45%)
   mean ± sd 0.96 ± 1.48 0.87 ± 1.66 0.84 ± 0.96 1.45 ± 1.81 0.12
BMI z-score               
   <95th %-ile (non-obese) 197 (82%) 88 (82%) 74 (81%) 35 (83%) 0.47
   >= 95th %-ile (obese) 43 (18%) 19 (18%) 17 (19%) 7 (17%)
   mean ± sd 0.43 ± 1.15 0.37 ± 1.15 0.55 ± 1.17 0.33 ± 1.13 0.96
Estimated GFR               
   mean ± sd 51.81 ± 21.11 51.61 ± 21.07 55.01 ± 19.09 45.38 ± 24.19 0.011
CKD stage               
   1 1 (0%) 0 (0%) 0 (0%) 1 (2%) 0.017
   2 32 (13%) 13 (12%) 7 (8%) 12 (29%)
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Descriptive Statistics Overall (N = 240) Controlled Hypertension (n = 107) Masked Hypertension (n = 91) Ambulatory Hypertension (n = 42) P-value†
   3 135 (56%) 60 (56%) 54 (59%) 21 (50%)
   4 59 (25%) 27 (25%) 27 (30%) 5 (12%)
   5 13 (5%) 7 (7%) 3 (3%) 3 (7%)
Hyperkalemia* (K+ > 5 mmol/L), n (%)               
   No 203 (86%) 86 (82%) 81 (90%) 36 (88%) 0.25
   Yes 33/236 (14%) 19/105 (18%) 9/90 (10%) 5/41 (12%)
Family history of hypertension*, n (%)               
   Yes 94 (44%) 43 (43%) 39 (49%) 12 (33%) 0.3
   No 121/215 (56%) 56/99 (57%) 41/80 (51%) 24/36 (67%)
Number of antihypertensive agents               
1 190 (79%) 93 (87%) 71 (78%) 26 (62%) 0.0018
   2 39 (16%) 11 (10%) 18 (20%) 10 (24%)
   3 8 (3%) 3 (3%) 2 (2%) 3 (7%)
   4 3 (1%) 0 (0%) 0 (0%) 3 (7%)
   mean ± sd 1.27 ± 0.58 1.16 ± 0.44 1.24 ± 0.48 1.60 ± 0.91 0.0018
Cumulative Relative Dose Index (tertiles & 
mean)               
   1st tertile (low dose) 80 (33%) 39 (36%) 35 (38%) 6 (14%) 0.0039
   2nd tertile (moderate dose) 80 (33%) 39 (36%) 27 (30%) 14 (33%)
   3rd tertile (high dose) 80 (33%) 29 (27%) 29 (32%) 22 (52%)
   mean ± sd 0.57 ± 0.55 0.52 ± 0.55 0.54 ± 0.50 0.78 ± 0.61 0.013
Mean Relative Dose Index               
   mean ± sd 0.43 ± 0.29 0.42 ± 0.29 0.40 ± 0.28 0.51 ± 0.32 0.16
Current Steroids Use, n (%)               
   No 220 (92%) 100 (93%) 85 (93%) 35 (83%) 0.099
   Yes 20 (8%) 7 (7%) 6 (7%) 7 (17%)
Antihypertensive Drug Class Use, n (%)               
   Renin-Angiotensin System Inhibitor 209 (87%) 105 (98%) 78 (86%) 26 (62%) <0.001
   Calcium Channel Blocker 44 (18%) 6 (6%) 17 (19%) 21 (50%) <0.001
   Diuretic 20 (8%) 8 (7%) 5 (5%) 7 (17%) 0.087
   Beta-blocker 12 (5%) 0 (0%) 5 (5%) 7 (17%) <0.001
   Other 9 (4%) 0 (0%) 5 (5%) 4 (10%)
* denotes missing values; please refer to denominator referring to total of known values
† P-values based on Chi-squared goodness-of-fit test for categorical factors (ie, sex, race, CKD diagnosis, obesity, hyperkalemia, family history of hypertension, steroid use, 
antihypertensive drug class use), Kruskal-Wallis one-way ANOVA for numerical or ordered factors (ie, age, maternal education, CKD onset, proteinuria, BMI z-score, estimated 
GFR, CKD stage, number of antihypertensive agents, cumulative relative dose index tertile, mean relative dose index)
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Table B2 (continued)
Table B3: Left ventricular hypertrophy absent vs. present
Descriptive Statistics Overall (N = 240) No LVH (n = 206) LVH (n = 34) P-value* OR [95% CI]**
Age (years)               
   mean ± sd 12.80 ± 3.68 12.93 ± 3.63 12.05 ± 3.91 0.23
Sex, n (%)               
   Male 142 (59%) 126 (61%) 16 (47%) 0.17 0.56 [0.27,1.17]
   Female 98 (41%) 80 (39%) 18 (53%)
Race, n (%)               
   Caucasian 164 (68%) 141 (68%) 23 (68%) <0.001
   African American 25 (10%) 16 (8%) 9 (26%) 3.45 [1.36,8.72]
   Other 51 (21%) 49 (24%) 2 (6%) 0.25 [0.06,1.10]
Maternal education*, n (%)               
   High school or less 95 (41%) 82 (41%) 13 (41%) 1
   Some college 58 (25%) 50 (25%) 8 (25%)
   College graduate 78/231 (34%) 67/199 (34%) 11/32 (34%)
CKD onset* (years before study entry)               
   n, mean ± sd 235; -8.28 ± 4.79 203; -8.56 ± 4.85 32; -6.50 ± 4.02 0.021
CKD diagnosis, n (%)               
   Non-glomerular 154 (64%) 135 (66%) 19 (56%) 0.37
   Glomerular 86 (36%) 71 (34%) 15 (44%)
Proteinuria (Urine protein:creatinine ratio)               
   Normal (<0.5) 132 (55%) 113 (55%) 19 (56%) 0.66
   Mild [0.5-1.0) 34 (14%) 31 (15%) 3 (9%)
   Moderate [1.0-2.0) 46 (19%) 41 (20%) 5 (15%)
   Severe (>2.0) 28 (12%) 21 (10%) 7 (21%)
     Normal-Mild (<1.0) 166 (69%) 144 (70%) 22 (65%) 0.55
     Moderate-Severe (>1.0) 74 (31%) 62 (30%) 12 (35%)
   mean ± sd 0.96 ± 1.48 0.93 ± 1.44 1.15 ± 1.72 0.82
BMI z-score               
   <95th %-ile (non-obese) 197 (82%) 171 (83%) 26 (76%) 0.12
   >= 95th %-ile (obese) 43 (18%) 35 (17%) 8 (24%) 1.50 [0.63,3.59]
   mean ± sd 0.43 ± 1.15 0.38 ± 1.13 0.74 ± 1.25 0.5
Estimated GFR               
   mean ± sd 51.81 ± 21.11 53.12 ± 21.01 43.87 ± 20.28 0.02
CKD stage               
   1 1 (0%) 0 (0%) 1 (3%) 0.025
75
Descriptive Statistics Overall (N = 240) No LVH (n = 206) LVH (n = 34) P-value* OR [95% CI]**
   2 32 (13%) 24 (12%) 8 (24%)
   3 135 (56%) 117 (57%) 18 (53%) 0.46 [0.18,1.18]
   4 59 (25%) 52 (25%) 7 (21%) 0.40 [0.13,1.24]
   5 13 (5%) 13 (6%) 0 (0%)
Hyperkalemia* (K+ > 5 mmol/L), n (%)               
   No 203 (86%) 178 (88%) 25 (76%) 0.12
   Yes 33/236 (14%) 25/203 (12%) 8/33 (24%) 2.28 [0.93,5.60]
Family history of hypertension*, n (%)               
   Yes 94 (44%) 85 (46%) 9 (30%) 0.15 1.98 [0.86,4.56]
   No 121/215 (56%) 100/185 (54%) 21/30 (70%)
Number of antihypertensive agents               
   1 190 (79%) 171 (83%) 19 (56%) <0.001
   2 39 (16%) 29 (14%) 10 (29%) 3.10 [1.31,7.34]
   3 8 (3%) 5 (2%) 3 (9%) 5.40 [1.20,24.39]
   4 3 (1%) 1 (0%) 2 (6%) 18.00 [1.56,207.92]
   mean ± sd 1.27 ± 0.58 1.20 ± 0.49 1.65 ± 0.88 <0.001
Cumulative Relative Dose Index (tertiles & mean)               
   1st tertile (low dose) 80 (33%) 72 (35%) 8 (24%) 0.26
   2nd tertile (moderate dose) 80 (33%) 67 (33%) 13 (38%)
   3rd tertile (high dose) 80 (33%) 67 (33%) 13 (38%)
   mean ± sd 0.57 ± 0.55 0.56 ± 0.55 0.63 ± 0.54 0.32
Mean Relative Dose Index               
   mean ± sd 0.43 ± 0.29 0.43 ± 0.29 0.39 ± 0.30 0.53
Current Steroids Use, n (%)               
   No 220 (92%) 190 (92%) 30 (88%) 0.66
   Yes 20 (8%) 16 (8%) 4 (12%)
Antihypertensive Drug Class Use, n (%)               
   Renin-Angiotensin System Inhibitor 209 (87%) 185 (90%) 24 (71%) 0.0048 0.27 [0.11,0.65]
   Calcium Channel Blocker 44 (18%) 31 (15%) 13 (38%) 0.0027 3.49 [1.59,7.70]
   Diuretic 20 (8%) 12 (6%) 8 (24%) 0.0018 4.97 [1.86,13.30]
   Beta-blocker 12 (5%) 7 (3%) 5 (15%) 0.017 4.90 [1.46,16.47]
   Other 9 (4%) 6 (3%) 3 (9%)
† P-values based on Chi-squared goodness-of-fit test for categorical factors (ie, sex, race, CKD diagnosis, obesity, hyperkalemia, family history of hypertension, steroid use, 
antihypertensive drug class use), Mann-Whitney U test for numerical or ordered factors (ie, age, maternal education, CKD onset, proteinuria, BMI z-score, estimated GFR, CKD 
stage, number of antihypertensive agents, cumulative relative dose index tertile, mean relative dose index)
** Unadjusted odds ratios [with 95% confidence intervals] calculated for selected factors with p-values <0.2, + symbol denotes invalid odds ratio due to occurrence of zero values
Table B3 (continued)
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C. Multivariate logistic regression model tables
Model including number of antihypertensive agents Model excluding number of antihypertensive agents
95% confidence interval 95% confidence interval
Variables Odds Ratio lower upper P-value VIF Odds Ratio lower upper P-value VIF
Age (+1yr) 1.056 0.96 1.164 0.27 1.267 1.061 0.966 1.168 0.218 1.264
Sex: Male 1.249 0.627 2.515 0.529 1.167 1.223 0.619 2.438 0.563 1.159
Race: African American 2.829 0.912 9.63 0.08 1.12 2.718 0.888 9.157 0.089 1.119
Race: Other 3.192 1.342 7.983 0.01 1.13 3.049 1.286 7.609 0.013 1.125
Maternal education: College (yes) 0.961 0.411 2.247 0.927 1.387 1.001 0.432 2.32 0.997 1.392
Maternal Education: Graduate (yes) 0.795 0.371 1.7 0.552 1.327 0.763 0.359 1.62 0.481 1.324
Primary renal disease (non-glomerular) 1.599 0.713 3.681 0.26 1.557 1.514 0.68 3.446 0.314 1.551
Proteinuria (moderate-severe) 1.415 0.674 3 0.36 1.148 1.341 0.646 2.804 0.432 1.127
Obesity (BMI >95th %ile) 0.823 0.344 1.928 0.656 1.108 0.841 0.356 1.954 0.689 1.109
CKD stage (4-5) 1.107 0.511 2.401 0.795 1.336 1.079 0.5 2.33 0.846 1.336
Hyperkalemia (K>5mmol/L) 0.41 0.137 1.119 0.092 1.151 0.401 0.137 1.072 0.078 1.165
Family history of hypertension (no) 0.828 0.425 1.605 0.577 1.103 0.882 0.458 1.693 0.705 1.086
Number of antihypertensive agents (+1) 2.682 0.915 9.323 0.09 3.628
Cumulative relative dose index (+tertile) 1.196 0.751 1.915 0.451 1.494 1.368 0.884 2.139 0.163 1.364
Current steroid use (yes) 1.575 0.422 6.092 0.499 1.143 1.377 0.374 5.273 0.631 1.123
Current antihypertensive use: RAASi (yes) 0.049 0.004 0.324 0.006 1.613 0.106 0.013 0.519 0.014 1.236
Current antihypertensive use: CCB (yes) 2.148 0.42 10.862 0.349 2.528 5.281 1.63 19.441 0.008 1.473
Current antihypertensive use: diuretic (yes) 0.116 0.015 0.712 0.026 2.14 0.32 0.069 1.309 0.121 1.302
Uncontrolled hypertension vs.
Controlled hypertension
Note: For binary variables, reference values for odds ratios are opposite from values in parenthesesFor continuous and 
ordinal variables value in parentheses refers to increment for corresponding odds ratio
Left ventricular hypertrophy present vs. Absent
Model including number of antihypertensive agents Model excluding number of antihypertensive agents
95% confidence interval 95% confidence interval
Variables Odds Ratio lower upper P-value VIF Odds Ratio lower upper P-value VIF
Age (+1yr) 0.906 0.77 1.058 0.222 1.729 0.924 0.793 1.073 0.304 1.57
Sex: Male 0.219 0.066 0.666 0.009 1.454 0.207 0.062 0.623 0.007 1.455
Race: African American 4.057 1.021 16.021 0.043 1.36 4.038 1.018 15.952 0.044 1.369
Race: Other 0.167 0.009 0.999 0.105 1.084 0.156 0.008 0.924 0.091 1.08
Maternal education: College (yes) 1.499 0.387 5.637 0.548 1.445 1.57 0.408 5.896 0.502 1.451
Maternal Education: Graduate (yes) 1.21 0.383 3.835 0.743 1.359 1.212 0.387 3.805 0.739 1.356
Primary renal disease (non-glomerular) 0.305 0.084 1.054 0.063 1.736 0.296 0.082 1 0.053 1.712
Proteinuria (moderate-severe) 1.198 0.363 3.754 0.759 1.276 1.169 0.356 3.645 0.789 1.284
Obesity (BMI >95th %ile) 1.646 0.398 6.084 0.467 1.29 1.724 0.429 6.277 0.42 1.287
CKD stage (4-5) 0.725 0.194 2.491 0.616 1.39 0.721 0.193 2.47 0.61 1.405
Hyperkalemia (K>5mmol/L) 1.726 0.447 5.968 0.402 1.206 1.743 0.468 5.864 0.382 1.203
Family history of hypertension (no) 1.107 0.379 3.377 0.853 1.195 1.192 0.418 3.582 0.746 1.162
Number of antihypertensive agents (+1) 2.492 0.384 14.267 0.313 6.314
Cumulative relative dose index (+tertile) 0.543 0.243 1.156 0.121 1.965 0.593 0.272 1.235 0.171 1.863
Current steroid use (yes) 0.668 0.078 3.826 0.677 1.221 0.591 0.074 3.197 0.575 1.227
Current antihypertensive use: RAASi (yes) 0.481 0.048 5.821 0.546 4.01 1.211 0.257 6.445 0.814 1.839
Current antihypertensive use: CCB (yes) 1.916 0.25 18.497 0.548 4.336 4.419 1.068 19.665 0.043 2.053
Current antihypertensive use: diuretic (yes) 1.888 0.206 20.104 0.581 2.701 4.627 1.055 21.119 0.042 1.166
Current antihypertensive use: beta blocker (yes) 2.638 0.15 54.361 0.512 2.863 8.021 1.124 61.874 0.038 1.406
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